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The search and development of technologies with the ability to replicate the complex characteristics 
of the human body has increased greatly in recent years. Organ-on-a-chip systems are clear 
examples, since they allow for the replication of a chosen organ including a representative 
population of cells and a controlled microenvironment with applied flow conditions, resulting in 
robust in vitro models that better recapitulate the in vivo tissue conditions, compared to standard 
2D or 3D culture methods. The main aim of this final degree project is to develop a bioprinted gut-
on-a-chip model to mimic the intestinal mucosa.  
Firstly, the intestinal mucosa is composed of physical and immune elements and has protective 
functions. In vitro models that grown monolayers of epithelial cell lines provide a limited 
representation of the intestinal mucosa. The in vitro model reviewed will mimic the in vivo 
characteristics of the native tissue including its specific 3D topography, the main cellular 
components and flow conditions, allowing for a better understanding of its performance. In order to 
incorporate the intestinal mucosa in our model, a microenvironment must be created in which the 
cell can live and perform their functions. Hydrogel co-networks based on GelMA and PEGDA have 
been postulated as the best candidate. The incorporation of microstructured hydrogels, that mimic 
the three-dimensional structure of the intestine, and the cell environment on the present gut-on-a-
chip model, better resemble the physiological conditions thus, having a strong impact on mucosal-
related disease modelling and drug testing. The method used to carry out the structuring of the 
hydrogel has been bioprinting. Specifically, the most commonly used bioprinting methods for the 
generation of lab-on-chip systems have been analysed and compared, to evidence, the main 
advantages of the Digital light processing projector-based stereo-lithography printing method, 
reported in this project.  
We have been able to optimize the geometry of the crypts, examine the swelling of the hydrogel 
and study the evolution of different microstructured hydrogels including the most representative 
stromal cell types embedded in the hydrogel. The main objective was to see if the cells were able 
to adapt to the three-dimensional topography of the hydrogel and, to determine, the compatibility 
of the printing method and of the gut-on-a-chip model. Finally, we found that the cells could grow 
and populate the microstructured hydrogel keeping high viability rates. Furthermore, it has been 
observed that the swelling of the hydrogel produces negative effects on the crypts, reducing 
considerable their size and causing them to have no physiological sense. 
The first part of this thesis describes the state of the art of organ-on-a-chip technology, the main 
bioprinting techniques and gives a brief introduction to the intestinal mucosa main characteristics 
to help the reader to better understand the requirements of this project. Also, a concise analysis of 
the market for this technology, historical evolution and key players is presented. Straightaway, the 
Regulation and Legal Aspects behind the present application are discussed. The second part of 
the thesis gathers a comparison, highlighting the main advantages, limitations, and applications of 
each bioprinting technique; choosing the most appropriate one for this work. In addition, a complete 
description of the methodology and results obtained during the project are reviewed in this part. 
Finally, in the third part together with the Technical and Economic prefeasibility, the implementation 
schedule of the project, the conclusions and future improvements are also reviewed. 
Keywords: Organ-on-a-chip / Gut-on-a-chip / 3D Bioprinting / Microfluidics / Hydrogels / 
Photopolymerization 
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“Our virtues and our 
failures are inseparable,  
like force and matter.  
When they separate,  
man is no more.”  
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Over the last few decades, attention has increasingly focused on assay platforms involving human 
cells to study tissue development and regeneration, developing systems for disease modelling or 
for therapeutic screening. Current efforts in drug development, toxicology or tissue development 
are often challenging by a lack of predictive models to reliably assess the physiological reaction of 
the human body to certain drugs or toxins [1]. In this sense, research has been performed in the 
field of microfluidics, predominantly in biosciences, pursuing the miniaturization and automation of 
diagnostic tests, laboratory experiments, and (bio)chemical processes. These platforms, known as 
lab-on-a-chip devices, are microfluidic cell culture systems that combine biofabrication, 
miniaturization and tissue-engineering components to recapitulate tissue-like characteristics such 
as 3D structure, physiology, pathology, and function of organs in vitro [2,3]. 
Rather than pipetting discrete quantities of liquids from one container to another, currently, the 
liquid in a microfluidic system flows via the miniatured channels of a manifold, thus reducing the 
sample volumes for testing. Other advantages of this “on-chip” technology over conventional 
culture systems rely on the multiplexing screening capability providing information in a fast and 
easy manner, and the possibility of reusing the devices [2].  
The liquid in these channels is normally moved by external pumps or pressure sources to which 
the fluidic chip is linked. In certain cases, to manage the applied pressures or balance the flow 
produced by the pump, the rate of flow is measured using different sensors. Reducing the size of 
the channels down to the micrometre range and liquid volumes to the range of microliters or even 
nanolitre, enable faster reactions [4]. Additionally, the smaller size of the complete system also 
means more feasible devices and lower costs of production. 
Bioprinting is considered one of the most advanced technology for producing biomimetic cellular 
constructs assembling scaffolds for growing tissues. These constructs can be used as in vitro 
models for many applications and combined with microfluidics enable the creation of Organ-on-a-
chip (OoC) devices simulating in vivo 3D microenvironmental constructions and colon architecture 
[5–7]. One of the most interesting examples is the human gut-on-a-chip technology to study disease 
development and progression with more accurate models, increase the efficacy of drug screening 
and development to overcome the main inconvenience of the conventional models that often rely 
on simple 2D culture systems. 3D bioprinting technology combined with microfluidics has gained 
interest in the last decade due to is high versatility and its highly automated fabrication system [8]. 
The aim of this technique is to fabricate 3D organized heterogeneous structures since this 
technology enables the precise patterning of a wide range of biomaterials with embedded living 
cells at pre-defined positions allowing for the development of on-chip models with high printing 
resolution and uniformity, fast fabrication, and high reproducibility, owing to the accurate control of 
the spatial distribution of biomaterials and cells during the printing process [8,9].  
Concerning quality, resolution and generation of precise complex tissue structures, biofabrication 
technologies that use light for the polymerization of biomaterials have made relevant advances in 
recent years [10]. The development of new photocurable resins with bioactive properties and the 
improvement of biocompatible and biodegradable photoinitiators have led to the growth of these 
technologies [10]. Digital light processing (DLP)-SLA projector-based stereo-lithography printing 
method is a high-resolution technology based on a controlled light projection through a transparent 
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window over a cuvette filled with photocross-linkable bioink creating three-dimensional structures 
[10,11]. The stereolithography system works with a light-emitting device (DLP projector) that 
polymerizes a GelMA – PEGDA hydrogel containing cells combined with LAP (photoiniator) and 
tartrazine [3,12]. Photocross-linkable hydrogel exhibits bioactive properties including high 
biocompatibility and enhanced mechanical properties compared with pure GelMA hydrogels [13]. 
Gelatin-based hydrogels mimic the extracellular matrix and are widely used to make multicellular 
models due to their advantages, which allow us to make customized bioink according to the needs 
of our system [13]. 
The intestinal mucosal barrier is an example of one of the most studied tissue models from the 
human body. Divided into three distinct layers and located in our intestines, it plays a significant 
role to effectively absorb nutrients and drugs, and furthermore in the regulation of the immune 
response against microbes and pathogens, maintaining the intestinal homeostasis [2,14,15]. Thus, 
intestinal mucosal models can be used to better understand the mechanisms involved in the barrier 
function and to study its drug permeability in the early stages of drug discovery [3]. The intestinal 
epithelium is lined with a single layer of polarized cells that presents characteristic three-
dimensional spatial features. Current in vitro models are 2D-based and therefore fail to capture the 
3D microenvironment present on the intestinal mucosa, which has been shown to have a direct 
impact on the function of the intestinal barrier [16,17]. This lack of tridimensionality has been 
contemplated as the main reason for a poor correlation between in vitro and in vivo models [16]. In 
this sense, there are different groups that are working on the development of new models that 
include this three-dimensional topography [16,17]. 
The present project will combine concepts of tissue engineering, microfluidics, and diagnosis to 
validate a complex in vitro model of intestinal epithelium using a gut-on-a-chip. The aim is to create 
a model of the intestinal mucosa, specifically creating gelatin-based hydrogels models of the colon 
that includes the characteristic 3D topography of this tissue and that contains the principal cell 
types. The objective is to be able to integrate the model within a PDMS chip to study the viability 
and evolution of the model. 
1.1 Structure 
Chapter 1 presents the aim of the project, the main objectives, and the scope. The background as 
well as the state of the art and a brief introduction about 3D bioprinting and the intestinal mucosa 
can be found in chapter 2, whereas Chapter 3 is dedicated to the market analysis of the organ-on-
a-chip devices. The regulatory context with the Legal Aspects is summarized in Chapter 4. Chapter 
5 discuss the cell culture models and their 2D and 3D variants as well as the most used bioprinting 
techniques. In this section, the materials and methods used in this project are also described. A 
detailed review of the results obtained and its discussion are presented in chapter 6. The temporal 
implementation of the project with the different organizing diagrams can be found in chapter 7. In 
chapters 8 and 9, the technical, and economic previability of the project is discussed. Finally, the 
conclusions and future perspectives of the project are discussed in chapter 10. An annex with 
complementary information is also included. 
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1.2 Aim of the Project 
The aim of this project is to optimize the fabrication of a hydrogel-based gut-on-chip model using 
an innovative 3D bioprinting technique. The system will combine a microstructured hydrogel 
together with an external casing containing the microfluidic connections, the fastener elements, 
and a transparent window. The microstructured hydrogel will be mimicking the intestinal stromal 
tissue present in the large intestine, taking into account both, its characteristic invaginations and its 
cellular compartment, including the most representative stromal cell types and the epithelial barrier 
surrounding a lumen-like central channel. This model will be used to better understand the 
mechanisms involved in the intestinal barrier function and its role regulating barrier dysfunction. 
The development of this project will take place at the Institute of Bioengineering of Catalonia (IBEC) 
in the Biomimetic systems for cell engineering group. The project will include (i) the design of the 
chip and its casing, (ii) the fabrication of the microstructured hydrogel using 3D bioprinting which 
will contain some representative cells of the intestinal mucosa, (iii) the hydrogel assembly onto the 
microfluidic chip, and finally, (iv) the characterization of the whole system, evaluating its 
functionality as in vitro model. 
1.3 Objectives and Scope of the Project 
The project has been developed during the period between February and June 2021. The study 
covers the design, fabrication and optimization of a gut-on-a-chip device mimicking the large 
intestinal mucosa. 
The objectives to be achieved in this project are the following: 
(i) Design of the chip structure, both the outer part and the microstructured hydrogel. 
(ii) Design the PDMS layers moulds that will contain the hydrogel. Find the accurate 
temperature and time to solidify the layers. 
(iii) Optimization of the printing parameters to achieve proper 3D microfeatures in the 
hydrogels resembling the CAD model designed.  
(iv) Design and testing of the external part of the microfluidic chip to allocate the 3D printed 
hydrogel. This casing will contain the microfluidic connections and should guarantee proper 
sealing of the hydrogel cavity. 
(v) Optimize the fluidic conditions to guarantee proper microenvironmental conditions inside 
the chip, allowing cell media exchange.  
1.4 Methodology 
This section provides an outline of the research methodology used to develop the gut-on-a-chip 
device. This project has been carried out mostly by doing experimental research. In addition, a 
search has been done in scientific publications to find out the state of the art of bioprinting and OoC 
technology to determine how the current models could be improved. In the same way, information 
and data necessary for the development of the project have been obtained from previous work 
performed in the group.  
The experiments consisted of developing the structural part of the chip. The chip consists of an 
external structural part that includes the casing, PDMS layers and cellular scaffold. First, the chip 
casing was designed and printed, which contained the PDMS layers. Secondly, the PDMS moulds 
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were designed and fabricated, their function was to house the hydrogel and form the microfluidic 
channel. Consequently, both the printing parameters to print the hydrogel and the three-
dimensional design of the structures contained in the hydrogel were optimized. Finally, the three 
parts were combined to create the gut-on-a-chip and improvements corresponding to the initial 
design were also implemented.  
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2. BACKGROUND OF THE PROJECT 
2.1 State of the Art 
The main conceptual problem of the current cell-based assays is that they rely on two-dimensional 
monolayer cellular cultures. The lack of tridimensionality (3D) implies that the results obtained with 
these tests do not represent what is happening in the organs (3D complex structures). Moreover, 
the development of microarchitectures resembling the human physiology is necessary to study, in 
a more reliable manner, the processes taking place in native tissues and organs [18]. In addition, 
the standard assays to replicate organs and tissues require a considerable volume of cells, 
reagents, nutrients, etc. The complexity of the standard cell-based assays is not enough to recreate 
the real intricacy of the living systems, so most of the current examples in literature lack of proper 
3D cell microenvironment [2,19,20]. The integration of cell culture models on microfluidic platforms, 
often known as Organ-on-a-chip (OoC) devices, offers new capabilities for analysing individual 
contributions of either cellular, physical or chemical parameters, allowing for the development of 
human-relevant disease models [2]. The success of the chip depends on how close their 
architectures are to the anatomical features [21]. The creation of OoC is useful in personalized drug 
screening and pathological studies since it is a platform that recapitulates the physiology of the 
patient much closer than other conventional methods [22]. OoC technology aims to replicate the 
structural, microenvironmental and physiological functions of the human organs building a specific 
human model and mimicking their mechanical and physiological cellular responses [7]. 
The applications of the OoC technology are wide and varied, depending on the tissue or organ to 
study. In the case of gut-on-a-chip systems, the main interest is focused on drug screening for 
pharma applications, creating relevant disease models [23]. In this way, Nikolaev et. al. 2020 
developed a biomimetic hydrogel scaffold recapitulating the relevant 3D geometry present in the 
small intestinal tissue (Figure 2.1) [24]. The platform consists of a hydrogel chamber flanked by two 
reservoirs and two external tubing to allow fluid irrigation and continuous perfusion. Through the 
seeding of cells to coat the surface of the hydrogel and continuous irrigation, they were able to 
prolong the survival of the artificial intestines up to 30 days. Additionally, they were able to study 
various phenomena and demonstrate that the chips shared many characteristics with real tissue, 
even seeing that there was a production of mucus [25]. Finally, the organoids were infected with a 
protozoan to study how infected cells active the inflammatory defence response against this 
pathogen, validating their use as a model for the development of effective therapies [25].  
Even though the use of Bioprinting to build scaffolds for growing tissues is recent, the last articles 
about this topic show that this technology is the most advanced technology for producing 
biomimetic cellular constructs [5]. Recent advancements in bioprinting techniques promoted the 
creation of novel OoC systems. The main advantage of 3D bioprinting in front of the conventional 
soft lithography techniques used for the fabrication of microfluidics is its versatility, allowing for 
combining multiple materials, biomolecules and cell types simultaneously, reaching prints in a 
faster and highly reproducible manner [26,27]. 
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Figure 2.1. Example of gut-on a chip microfluidic platform containing intestinal crypts. Adapted from Nikolaev et. al. 2020. [25]  
Culturing human cells on chips enables studies of pharmacokinetics in specific individuals, 
facilitating personalized medicine. Different possibilities for OoC technology can be implemented 
for different applications such as models for disease and cancer, studies of specific biological 
mechanisms, drug discovery and toxicity tests, and regenerative medicine [28]. Considering the 
conventional solutions in which the tests were mostly performed on animals, it raises a big 
controversy on the ethical front in addition to providing results that cannot always be applied to 
humans [29]. Despite some characteristics of the human gut are remarkably different from that in 
mice, such as the gut microbiome where the 85% that colonizes in humans does not exist in mice, 
animals models are used for testing before performing clinical trials with human beings, which 
usually fail to predict efficacy and safety of novel drugs [2,30]. 
Modelling physiological and pathophysiological processes in the intestinal tract outside the human 
body is a huge challenge. Despite several published works in the field, most researchers and 
clinicians base their studies on simplistic 2D cell culture models where only static conditions can 
be applied [31]. Systems based on bioreactors and microfluidic devices have been developed as 
alternative culture methods to better mimic the cellular microenvironment, allowing for the 
application of dynamic flow conditions inducing gradients of shear stress on the cells in the luminal 
cavity as occurs in vivo.  
Great progress has been made in advancing in vitro models through 3D and microfluidic models. 
Gijzen et. al. 2020 introduced a microfluidic platform applicable for studying inflammatory 
processes called OrganoPlate [32]. The developed chip comprises three adjacent culture channels 
and its corresponding inlet and outlet. The chip consists of two medium perfusion channels and 
one gel channel separated by capillary pressure barriers called phaseguides. The three channels 
join in the centre of the chip, where they are separated by two phaseguides. The central channel 
serves as an observation window to monitor cells, readout, and see their progression. Firstly, a 
collagen-I extracellular matrix (ECM) is patterned into the middle channel of the chip. After this, the 
epithelial cells are seeded on the top perfusion channel, facilitating the cells to settle against the 
ECM. After some days, differentiated cells are added to the bottom channel. In addition, in order to 
better recapitulate intestinal physiology and increase the complexity of the model, various cell types 
were added [32]. 
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On the other hand, Shim et. al. 2017, reported in vitro gut model incorporating a collagen scaffold 
that mimics the human intestinal villi [33]. The topography of the intestine was modelled by combining 
different fabrication techniques, using positive moulds of PDMS the hydrogel scaffold was 
developed. Cells were seeded on the top of the collagen scaffold, where they formed a uniform 
monolayer across the collagen villi surface. This structure was integrated into a microfluidic system 
that consists of three layers of PDMS, a glass and a polyester membrane. The basolateral reservoir 
was connected below the scaffold and the apical one above [33,34]. 
Last of all, one of the most recent examples of these complex systems is the gut-on-a-chip model 
developed by Donald Ingber and co-workers [2]. They present a microfluidic chip with two 
microchannels separated by a porous and flexible membrane, where they seed human intestinal 
cells on top of 3D structures that mimic intestinal villi and crypts (Figure 2.2) to study features of 
the barrier and transport functions [20,35]. Moreover, they include an endothelial barrier on the lower 
surface of the same membrane mimicking vasculature to study the tissue-tissue interface [2]. These 
characteristics offer relative advantages to use these models to simulate the barrier between the 
intestinal lumen and vasculature. Some devices more sophisticated integrate multiple chambers 
with different types of cells. The Wyss Institute at Harvard University recently designs a 
mechanically active gut-on-a-chip based on the models previously reviewed, where two chambers 
on both sides of the principal channel replicate the peristalsis using vacuum. According to the 
results obtained, the use of microfluidics and replication of the peristaltic movement allows the 
development of more complex disease models, drug development and personalized medicine [2,36]. 
Specifically, cells in this OoC interact with the membrane while experiencing peristalsis-like 
deformation in vitro similar to those experienced by the intestinal tissues. 
 
Figure 2.2. Illustration of the cross-section of a mechanically active human gut-on-a-chip with a central chamber and two vacuum 
chambers used to perform mechanical deformation. [2] 
Different studies suggest that current in vitro intestinal models lack physiological relevance features 
that might play a critical role in some disorders [2,33]. The models previously reviewed present 
various approaches to mimic the three-dimensional structure of the intestine and to create human-
relevant disease models [2]. However, in all these models the intestinal mucosa is not present. 
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This structure and composition constitutes a critical immunological barrier and is responsible for 
regulating inflammatory processes, preventing the passage of undesirable luminal content while 
preserving the ability to absorb nutrients [37,38]. 
2.2 The Intestinal Mucosa 
The intestinal epithelium is part of the intestinal mucosal barrier which is composed of physical, 
biochemical and immune elements and has protective functions separating the digestive 
environment and the body [2]. In addition, this barrier is actively involved in processes of drug 
absorption and metabolization [14]. The dysfunction of the intestinal mucosal barrier is involved in 
numerous health problems and diseases, such as intestinal bowel diseases (IBDs) and Chron’s, 
resulting in variations in its permeability that can alter the pass of microbes, microbial products, or 
foreign antigens into the body [14].  
The intestine is a highly complex organ not only for its structure which is not easy to replicate using 
the traditional methods. This was first studied by March’s group [39] who construct a 3D hydrogel 
structure on-chip and saw that this structure was closer to the intestine in shape and distribution 
density than the conventional methods used to mimic the intestine [23]. For these reasons, the 
development of alternate intestinal in vitro models is crucial for the gastroenterology field of 
research [40]. 
The complete simulation of the microenvironment mimicking the intestinal mucosa requires 3D 
models capable to reproduce the intestinal mucosa tissues. These systems provide a 3D 
architecture for cell growth and interactions cell-cell and cell-ECM making them better to mimic in 
vitro intestine microenvironment [15]. Few studies focus on the necessity or creation of 3D models 
for improving the actual models of drug absorption reconstructing the intestinal mucosa tissue 
through 3D models. 
The objective of bioprinting is to develop OoC that should reflect different functionalities and 
structures of the human organs on microfluidic chips. This is widely used to validate the therapeutic 
efficacy of drugs, the study of disease mechanisms, regenerative medicine, etc. [41] Over the past 
five years, the complexity of the engineered intestine is increasing, which favours a better 
development OoC models and therefore more complex disease models, improved results in drug 
development and facilitates personalized medicine [2].  
In vitro models that grown monolayers of epithelial cell lines provide a limited representation of the 
intestinal mucosa, only doing a simplistic representation of the epithelial component [3]. However, 
Bosman et. al. 1993 demonstrate that interactions between the epithelium and the stroma are 
important to maintain the integrity of the intestinal mucosa [3,42]. Therefore, according to Vila et. al. 
2020, to reduce the difference between in vitro epithelial cell-based models and in vivo experiments 
is necessary the development of more physiologically relevant 3D intestinal mucosa-like models in 
vitro models able to represent the epithelial and stromal compartments [3,15,43].  
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Figure 2.3. Representation of epithelial tissues, with their native 3D architecture, conventional 2D cell cultures and novel 3D 
approaches of cell culture. Adapted from Torras et. al. 2018. [44]  
In conclusion, given the importance of the mucosa in regulating the functioning of the intestine, it 
is necessary to incorporate it into these gut-on-a-chip systems. However, in order to incorporate 
these structures, a microenvironment should be created in which cells can live and perform their 
functions. For this reason, with the aim of developing these functions, a biocompatible and 
biodegradable material that can be remodelled by cells should be created. In this sense, hydrogels 
have been postulated as potential candidates. 
2.3 Hydrogels 
To build the 3D scaffolds we have chosen hydrogels, polymeric materials with a high water 
content. Both of natural or synthetic origin, hydrogels can mimic a large variety of tissues due to 
their excellent characteristics, as high biocompatibility and tuneable physicochemical properties; 
which are strongly dependent on their composition and fabrication technologies [45]. Alginate, 
gelatine, agarose, chitosan, collagen, hyaluronic acid, poly (vinyl alcohol) and poly (ethylene glycol) 
are some examples of the most widely used materials to form hydrogels for tissue engineering 
scaffolds. 
During the last five years, the biomimetic systems for cell engineering group at IBEC has developed 
hydrogel co-networks based on gelatin methacryloil (GelMA) and poly(ethylene glycol) diacrylate 
(PEGDA) that photopolymerize in the presence of either UV or visible light, with the main objective 
of creating 3D functional in vitro models of the intestinal mucosa [3], approaching the in vivo tissue 
composition and architecture. The resulting GelMA-PEGDA hydrogel co-network provides the 
required features of both the epithelial and stromal compartments [3]. On one hand, GelMA is a 
natural polymer that resembles some essential properties of the native ECM, providing 
biodegradation and cell adhesion sequences. Its composition is mechanically and biochemically 
tuneable according to the required properties, but lacks long-term mechanical stability. On the other 
hand, PEGDA is a synthetic (non-biodegradable) and highly stable polymer that does not present 
cell adhesion motifs; but it has good mechanical properties [17,45–47]. PEGDA is acquired by the 
derivation of PEG, a hydrophilic and biocompatible polymer that is a non-cell adhesive. Substituting 
terminal hydroxyl groups of PEG with acrylates PEGDA can be fabricated [46]. To perform this work, 
a hydrogel composed by GelMA-PEGDA co-network has been used. However, its composition has 
been tuned to adapt the mixture to the bioprinting process. 
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The main requirements the hydrogel used in this project should fulfil are: (i) to be consistent enough 
to sustain the culture on top forming a mature epithelial monolayer, but at the same time (ii) be 
porous and soft enough allowing the cells embedded in (the ones mimicking the stromal 
compartment) a proper growth rate and functioning [3,16,48]. 
GelMA-PEGDA hydrogel co-network should be crosslinked chemically forming covalent bonds 
resulting in a permanent, stable, and strong hydrogel network [3,15,49]. In our case, a 
photocrosslinkable hydrogel was developed in which biocompatible photosensitive compounds 
were added to the polymer mixture. The photoinitiator used was Lithium phenyl-2,4,6-
trimethylbenzoylphosphinate (LAP) which in presence of visible a light source induces the photo-
crosslinking of the hydrogel. The hydrogel co-network should be consistent enough to sustain the 
culture on top forming a mature epithelial monolayer, but porous and soft enough to allow the cells 
embedded in (stromal compartment) a proper growth rate and functioning [3,16,48]. 
Finally, it is necessary to structure the hydrogels to give them the 3D geometry that characterizes 
the intestine. For this, it is necessary to polymerize the hydrogel using 3D bioprinting techniques 
with the aim of polymerizing the hydrogel with a specific microstructure. 
2.4 3D Bioprinting Techniques 
3D bioprinting techniques offer the possibility to reproduce complex three-dimensional structures 
in a controlled and reproducible manner, due to its high versatility [5,7]. Moreover, aspects such as 
the porosity of the printed material and the interconnectivity of the printed network, which are 
difficult parameters to control using conventional fabrication methods, can be controlled and tunned 
in demand. Based on automated dispensing systems, these group of techniques allows via the 
controlled precipitation of biomaterials and cells to assemble tissue scaffolds, orchestrating a fully 
integrated and functional biological microenvironment [7]. However, before starting with the printing 
it is very important to investigate certain aspects that will influence the printing results, such as the 
printing parameters, the composition of the bioink to be used (including or not cells), and the main 
properties of the resulting scaffolds, to choose the most suitable printing technique for the chosen 
application.  
Basically, there are four main 3D bioprinting techniques (Figure 2.4): [6] 
a) Digital light processing (DLP), based on planar pattern projection. A more detailed study of 
this technique is done in sections 5.1.3 and 5.1.4. 
b) Fused deposition modelling (FDM), based on the local and continuous deposition of a 
material on a filament. This technique is reviewed in section 5.1.1. 
c) Inkjet printing (IP) based on the controlled deposition of material using microspheres. More 
information of this technique can be found in section 5.1.2. 
d) Selective laser sintering (SLS), based on the local and in-situ sintering of different material 
powders. 
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Figure 2.4. Four typical 3D printing processes. From left to right: Digital Light Processing (DLP), Fused deposition modelling 
(FDM), Inkjet printing (IP) and Selective laser sintering (SLS). [6] 
All the above-mentioned bioprinting processes involve the same preparation steps, which should 
be performed following the order described below: [6] 
1. Data acquisition: The data used to build the model can be obtained using different imaging 
techniques such as X-ray, microscopy and computed tomography (CT), or directly created 
by using dedicated software for 3D. When the 3D model is ready, its volume should be 
divided onto 2D horizontal slices. One on top of the other will recreate the full 3D model. 
2. Material selection: this step includes the selection of the material to be printed, which can 
be composed of different types of polymers and include cells, growth factors and other 
chemical compounds. The combination of all these factors is what it is known as bioink. 
Its proper selection is a key aspect to guarantee the integrity of the prints, providing good 
biocompatibility and mechanical properties. 
3. Bioprinting: the process of bioprinting needs an appropriate configuration of the parameters 
and observation during all the process. These parameters may vary as a function of the 
technique chosen and also the bioink used. 
4. Print validation: final step in which the quality of the prints and their functionality is checked. 
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3. MARKET ANALYSIS 
According to one of the latest market analyses report published on Values Reports and fulfilled at 
the beginning of the year, the OoC market is segmented by type, application, regions and key 
players [50]. Despite the economic situation derived from the pandemics, the market size is projected 
to reach 303.6 Million USD by 2026 and increase the Compound Annual Growth Rate (CAGR) of 
39.9% during the period 2021-2026 [51]. 
3.1 Sectors leading the market  
In the last 20 years, it has been observed an increasing expense in the development of drugs, while 
the number of drugs approved annually for commercialization decreases. This is one of the factors 
that has made pharmaceutical companies the leading sector in the OoC technology market [51]. 
The total costs to develop a drug are estimated nearly 2.5 billion dollars on average and, two-thirds 
of the total cost correspond to the clinical trial stage. Improving the predictive power of preclinical 
screening using on-chip technology would allow early detection of ineffective drugs, facilitating their 
discarding earlier and avoiding unnecessary spending [51].  
On the other hand, the growing emphasis on developing reliable alternatives for animal testing 
models had increased the number of partnerships and collaborations between pharmaceutical 
companies and OoC manufacturers [52].  
3.2 Historical evolution 
As shown in Figure 3.1, according to Zhang & Radisic (2017), the number of articles per year about 
the organ-on-a-chip is growing with an exponential shape [51]. The topics related to Organ-on-a-
chip and Microfluidics are being investigated in recent years and it is likely that the curve will 
continue to grow in the coming years [51]. The excitement over OoC technology rise in 2015 after 
the publication of a Lung-on-a-chip device mimicking the interface between endothelial and alveolar 
cells and aspects such as pulmonary inflammation or infections [53]. 
 
Figure 3.1. Rise in academic publishing in OoC on Google Scholar. Representation of the number of publications per year, where 
the topic of the article was directly related with the key words “Microfluidics” and “Organ-on-a-chip” from 2000 to 2015. [51]  
3.3 Future Perspective 
Nowadays, the market of organs-on-chips is emerging and is expected to reach 303.6 Million USD 
by 2026 while in 2020 the market was of 41 Million USD with a CAGR of between 35% and 40% 
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[50,54]. This growth in the market is mainly driven by the fact that this type of technology has many 
advantages with respect to the conventional ones and also an important future. In addition, the 
search for alternatives for the animal testing models and the increase of capital in research which 
develops organs-on-chips has favoured this market rise [30]. Furthermore, the growing need for 
early detection of drug toxicity with the objective to minimize the financial losses due to drug failure, 
causes significant investments by pharmaceuticals. To drug testing and development, OoC 
technology represents a good platform to study certain disease processes, using cells taken from 
patients. This makes it possible to develop personalized medicine in the future using samples taken 
from the patients [55].  
That is the reason why the end-user of this technology can be segmented into: pharmaceutical and 
biotechnological, companies, and academic and research institutions. The OoC market can be 
divided into the following aspects: 
• Type: the market can be segmented into different organs the most important are liver, 
lung, heart, intestine and kidney, among others [54]. The more interest in studying the 
organ, the more investment and therefore, the more market there is. 
• Application: Depending on the objective of the model the market can be divided into 
different sectors of use. The most important applications are physiological development, 
personalized medicine, drug discovery and toxicology research, among others [51,55]. 
• Region: North America is expected to have the highest market growth and therefore, the 
highest CAGR grow of the market, followed by Europe. The continent that will experience 
the greatest market increase over 2010 will be Asia but will not reach the market size of 
Europe or North America [54]. 
3.4 Key Players 
According to Low et. al. 2021, the market is emerging, and the market concentration is in the middle 
point between a consolidated market (dominated by one to five major players), and a fragmented 
and highly competitive market (without dominant players) [50,56]. Nowadays there are some 
companies that are prominent key players in this global market, most of them are in the United 
States. Some examples of these companies are: Emulate Bio, Hurel Corporation, Nortis and 
Ascendance Biotechnology in the United States, CN Bio Innovations in the United Kingdom and 
Insphero AG in Switzerland.  
In Section 4.1 is reviewed part of the regulation developed in the UK by the Medicines and 
Healthcare products Regulatory Agency since it is one of the first countries in Europe that is 
developing new regulations about OoC devices [57]. Figure 3.2 shows the two main types of 
companies developing organs-on-a-chip systems: those that develop body-on-a-chip models, 
which include more than one organ per chip, and those that are focused on only one organ, what 
is known as Tissue interface-on-a-chip). Within this last group, we find Emulate bio which is 
developing gut-on-a-chip models, among other organs [51].  
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Figure 3.2. Some of the prominent key players in the organ-on-a-chip and body-on-a-chip market [51]. 
The most important finding of the global OoC market is that the Lung-on-a-chip organ type is 
expected to have the largest market share. In the last years, the interest and investment in gut-on-
a-chip, is increasing, the drug development and drug discovery is the application that is growing 
faster. Finally, the pharmaceutical and biotechnological companies are expected to be the major 
end-user of the OoC devices [51,52].   
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4. REGULATION AND LEGAL ASPECTS 
As we have reviewed during this project the organ-on-a-chip technology presents many 
advantages, and they are designed to be able to replace the experiments with animals and to obtain 
a better model of diseases [30]. That is the reason why the regulatory processes on the different 
agencies are speeding up. One example is the US Food and Drug Administration (FDA), which 
have set up a program to develop the regulation of human tissue chips to replicate the function of 
the structure of human organs [58]. The lack of harmonization between the FDA and the EU 
European Medicines Agency (EMA) increases the absence of clear regulation and legislation for 
3D bioprinted tissue-engineered constructs [8]. The key regulatory considerations involved aspects 
such as the materials used, processes performed and the products obtained [8]. 
4.1 Regulatory Context 
The Regulatory context in the OoC field is complex since the regulation depends on the final use 
of the device. In the case of drug screening the regulatory framework would be focused on the drug 
approval. That means that the OoC should approve the regulation for a specific purpose, usually 
for the purpose for which it was designed. There is no generic regulation for this type of technology. 
Regulatory can represent a significant barrier in the OoC implementation. The early stage of the 
technology involved in this project causes an early stage of the regulation. It is expected that in the 
next years more regulation will be accepted [54]. The Medicines and Healthcare products Regulatory 
Agency (MHRA) in the United Kingdom, where is located CN Bio Innovations one of the most 
important companies of OoC technologies, is studying the regulation of these technologies and 
wants to improve the regulatory routes to validate it. The method used by regulators is that they 
encourage the companies to share the data of the models to demonstrate the potential utility [59].  
Along this project, the use of cells has been necessary, especially in later stages, and for their use 
different authorization and licensing were required. The regulation in Europe is defined by three 
directives: 2004/23/EC, 2006/86/EC and 2006/17/EC [60]. The directives define the regulation and 
legal aspects of the donation, procurement, testing of human tissue, and cells. The implementation 
is mandatory for all the state members of the European Union. Also, the directive 2003/94/EC is 
important since legal aspects of Good Manufacturing Practices for advanced therapies are 
specified [60]. 
In Europe, October 1, 2017, began a project called ORCHID (Organ-on-a-chip Development), it 
includes 6 universities from Spain, Germany, France, Netherlands, and Belgium. All these 
universities were coordinated by the Stichting Institute for Human Organ and Disease Model 
Technologies in the Netherlands to study the development of this technology. The total contribution 
was more than 520.000 €, and the main objectives were [54,61,62]:  
• Evaluation of the technology, a complete study of the state of the art and unmet needs. 
• Identification of ethical issues, establishing standards and identifying measures for a 
regulatory implementation.  
• Analysis of economic and societal impact, training, and education.  
• Developing a roadmap that will guide the required R&D efforts.  
• Raising awareness and building the ecosystem for OoC technology through a digital 
reference platform 
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With nearly two years of research, the project ended on September 30, 2019 [61], and the results 
show that a similar effort than in US should be done by the European Medicine Agency (EMA) in 
EU. In US the FDA help the independent testing centres and do active contribution to help the 
development of the OoC technology [61]. 
4.1.1 Standardization 
The standardization process is also a heavy barrier that should be overcome. As is reviewed in the 
(Mastrangeli, Mar. 2019) [54] one of the problems of the OoC technology is the absence of 
standardization. Aspects as the shape, interfaces, sizes, quality, tissue types, or ways of use, can 
change in different companies or institutes and it may cause compatibility problems. This process 
of regulation may take years before these technologies are accepted by regulatory agencies. 
4.2 Ethical Context 
The absence of any ethical concern regarding animal studies is introducing new ethics in science. 
The objective is to introduce the Animal welfare and change the use of animals in research. One 
of the first fields in which the use of animals was banned is in the process of testing cosmetics 
since it is banned in the European Union, United Kingdom, India, Israel, and Norway [50,52,54].  
The use of OoC is considered as a replacement alternative for big part of the remaining animal 
studies since the ethical issues presented by the OoC are less than the use of animals in research 
and experimentation. Meanwhile, during clinical studies and testing compounds, innumerable 
animal lives are lost and often the results demonstrate a lack of accuracy to mimic human 
pathophysiology and fail to predict the response of the organ [52]. A better reproducibility of the 
experiments and a more balanced and accurate drug discovery process can be performed using 
human models in vitro in order to accelerate and advance personalized medicine and the 
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5. CONCEPTION ENGINEERING 
Given the initial specifications of the project, a chip was designed in order to store the hydrogel, 
which contained the microstructure that mimicked the large intestine and various specific cell types 
of the intestinal mucosa. At the beginning of the project, it was decided that the polymerization and 
structuring of the hydrogel would be performed by 3D bioprinting. We hypothesize that the 
combined effect of the 3D structure of the hydrogel acquired with the bioprinting technique, and the 
fluidic shear can provide the cells with the appropriate stimulus to induce further differentiation and 
improve physiological relevance. 
5.1 3D Bioprinting Methodology 
To develop the initial objectives that have been considered in this project, a series of bioprinting 
technologies/techniques have been identified that could be used (individually or in combination with 
other techniques) for the development of the in vitro model. On one hand, there are the standard 
culture models, which basically consist of seeding cells on 2D flat and hard substrates [7]. Culture 
uniformity is their main advantage, but they lack 3D topography and the possibility to recreate the 
stromal compartment in a controlled manner. On the other hand, 3D bioprinting offers the ability to 
construct microstructured tissues layer-by-layer with high precision and allows the inclusion of 
complex physiological structures [63].  
5.1.1 Extrusion-Based Bioprinting 
Extrusion-based bioprinting has been employed in recent years by researchers as a good cost-
effective alternative to OoC fabrication [6]. The most important advantages presented by this method 
are its versatility, inexpensive equipment (good affordability) and the possibility to print a wide range 
of biomaterials. The technique is based on the extrusion of the bioink to form a continuous micro-
filament which is deposited on a substrate that can be solid, liquid or a material derived from gel [6]. 
The different methodology used to extrude the material is the main difference between the 3 types 
of methods that can be applied to do this category of bioprinting: 
• Pneumatic-driven extrusion: this method utilizes compressed air to extrude the material. 
• Piston-driven extrusion: this method utilizes a mechanical system to extrude the material. 
A piston-driven extrusion is the most common. This method is highly recommended for 
extruding biomaterials with a high viscosity. 
• Screw-driven extrusion: this method also used a mechanical system to extrude the material 
but in this case, a screw-driven extrusion is used. This system is similar to the Piston-
driven system but using a screw, more pressure is provided which might damage the cell 
in the bioink.  
In general, the Piston and Screw-driven methods provide a good printability and higher resolution 
using semi-solid or solid-state biomaterials. The main disadvantages of both techniques are that 
the volume of impression is limited and the process of cleaning and disinfection is more complicated 
[6]. Also, the cost of the equipment is higher than the Pneumatic-driven method. Finally, the three 
principles are represented in Figure 5.1. 
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Figure 5.1. Illustration of extrusion-based bioprinting. A) Pneumatic-driven bioprinting. B) Piston-driven bioprinting. C) Screw-
driven bioprinting. Adapted from Zeming et. al. (2019). [6] 
The main reason why the extrusion bioprinting method is not used in this project is because it 
presents problems with the cells. The cells suffer a high level of shear stress when passing through 
the extrusion system (syringe). In all three principles, the pressure is enough to reduce the viability 
of the cells within the printed matrix, falling in values by 50%. 
5.1.2 Droplet-Based Bioprinting (Inkjet Printing) 
To obtain a higher resolution we can use this technology based on droplets as the basic unit. The 
basic principle is the use of droplets which makes it a very simple model and with high control of 
biologic, including cells, growth factors, biomaterials, etc. In the same way, as the Section 5.1.1, 
the difference in the principles depends on the method used to form and release the droplets, which 
in this case will be the bioink [6]. There are three different principles to print using this technology: 
- Inkjet bioprinting: Can be divided into two types of printing, continuous inkjet and drop-on-
demand. The continuous inkjet has higher frequencies but achieves smaller volumes while 
the drop-on-demand has lower frequencies and volumes but higher spatial resolution [6]. 
- Electrohydrodynamic jetting (EHDJ): is based on electromagnetic fields. Placing two 
electrodes with a differential of potential is possible to form and release the droplets [6]. 
- Laser-assisted bioprinting: The most complex using droplets, is necessary a Pulsed Laser 
to excite the layers and three layers; one must be a glass/quartz layer, the second one 
must be the absorbing layer and finally the bioink. The excitation of the Glass/Quartz layer 
will cause the formation and release of the droplets [6]. 
The most common methods are the inkjet bioprinting (Figure 5.2) and the Laser-assisted bioprinting 
(Figure 5.2). The main disadvantage of this category is the lack of precision in the size and 
placement of the droplet. Also, requires a low viscosity bioink, which rejects several bioinks used 
for bioprinting [6,48,64]. 
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Figure 5.2. Two examples of Droplet-base bioprinting. A) Inkjet bioprinting method. B) Laser-Assisted method. Loai et. al. (2019). 
[65] 
5.1.3 Photocuring-Based Bioprinting 
The photocuring-based bioprinting also named vat polymerization can be divided into 
stereolithography (SLA) and digital light processing (DLP). 
- SLA: using this method a laser provided the energy to form the covalent bonds between 
adjacent polymer chains in bioink solution. The laser is reflected in a mirror and does an 
appropriate point by point moving in X and Y directions [6]. (Figure 5.3) 
- DLP: however, during the DLP it solidifies a complete layer at once instead of point by 
point. It prints the bottom layer first, and each new layer is above the previous one [6]. 
(Figure 5.3) 
This technique is based on the solidification of photosensitive polymers to form structures under a 
precisely controlled lighting with high precision [64]. The most common uses of these technologies 
are the creation of cell-free scaffolds, but in recent years cell-laden scaffolds have been created. 
As it is highlighted in (Zeming Gu et. al, 2019) [6] this technology compared to other methods of 
bioprinting, usually has significant improvement on printing resolution and printing speed which 
makes a good method for bioprinting. 
Unlike the previous methods, this one works by polymerizing the bioink with light, patterns of light 
and dark pixels are projected and therefore it is necessary that this one contains light-curing 
material [66]. It should polymerize at the same wavelength of the light source coupled to the printer. 
Typically, the light source is a projector (visible, white light spectra) or an array of LEDs (of a specific 
wavelength). One advantage of these systems is that most of them use an open-source 
programming code coupled to Arduino platform, that can be easily modified to reach the end user’s 
requirements. Its lower price together with the possibility of using custom resins as bioink [49]. Make 
this approach one of the most widely adopted by research groups worldwide. 
Finally according to Yong He et. al. 2020, this technique has some inefficiencies such as its non-
ideal density and uniformity of loaded cells [64]. The light exposure used to polymerize the bioink 
can negatively affect the cells and nontoxic photoinitiators should be used to non-affect the activity 
of the cells [64]. It is expected that DLP-SLA replaces the extrusion-based bioprinting as the most 
used method in the near future [64]. 
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Figure 5.3. Simplified schematic drawing of the SLA and DLP principles. A) Schematic drawing of the SLA bioprinting set-up and 
the scanning system. B) Schematic drawing of the DLP bioprinting set-up, the digital micromirror device and the laser. Adapted 
from Long Ng, et. al. (2020). [8] 
Table 5.1 summarizes the most relevant parameters of the above-mentioned 3D bioprinting 
methods. In the first column, different parameters are analyzed and the three methods have been 
classified between the levels, Low, Medium and High. 
Table 5.1. Comparison of the common bioprinting categories. Adapted from Miri et.al. 20219, Murphy & Atala 2014 and Ji & 
Guvendiren 2017. [21,67,68] 
Parameter Extrusion Inkjet Photocuring 
Speed Medium Low High 
Cost Low Low Medium 
Resolution 100-500 μm 100-500 μm 20-100 μm 
Flexibility Low High High 
Commercialization Medium High Low 
5.1.4 Method Selected 
Analysing all the features and parameters of the three common bioprinting categories, the best 
method for this project is the digital light processing - stereolithography (DLP-SLA) 3D 
bioprinting technique. In addition to being a technique that can be used for the fabrication of 
structured hydrogels with embedded cells, the same technique will allow for the fabrication of 
pieces and moulds for the development of the platform that would contain both the hydrogel with 
the cells and the microfluidic connections. This method allows the crosslinking of soft polymers 
using visible light, for that is required a special bioink containing light-curing materials. A more 
extensive explanation about this bioink can be found in sections 5.2.1 and 6.2. 
As we have reviewed in section 5.1.3 a good way to obtain this type of bioprinter is by modifying a 
commercially available printer. In this way, we can avoid the problem of low commercialization of 
these printers presented in Table 5.1. In this project, a Solus 3D printing equipment (Junction3D) 
has been used (Figure 5.4). It was previously adapted by lab members for printing scaffolds with 
embedded cells using reduced bioink volumes and increasing cell viability. 
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The system consists of the following main components: a facing-down printing support coupled to 
a Z-axis motor, a resin vat with a transparent window, and a beam projector. Also, a customized 
aluminium printing support and aluminium vat were designed for printing small scaffolds (Figure 
5.4). The objective is to illuminate the mirror under the printer and allow the process of photocuring 
(Figure 5.4). 
An important parameter to consider is the cell damage due to infrared radiation (IR) exposure, to 
avoid it a short pass heat protection filter (Schott) was added to the output of the projector (Vivitek). 
The structure of the 3D printed pattern is in the vertical direction, layer by layer. Printing parameters 
such as the thicknesses of the printed layers, the brightness of the light and exposure times can 
be adjusted as a function of the print design and the bioink composition, to get the proper results, 
the optimization of these parameters is reviewed in Section 6.3.2. 
The gut-on-a-chip should replicate different parts of the intestine to perform a good replication of 
the physiology of the human gut. The need to perfuse the hydrogel with cell culture medium, force 
the integration of the hydrogels with the embedded cells in a perfusable platform. This platform is 
composed of different layers of poly(dimethylsiloxane) (PDMS), (Section 6.1.2), and through an 
instrument and microfluidics, we can introduce cell culture medium to the hydrogel to be able to 
perfuse the chip correctly so that the cells can survive inside the gel (Section 6.4). 
        
Figure 5.4. From left to right: Commercial Solus 3D printer and a Vivitek projector and illustration of a visible-light-based 
stereolithography 3D bioprinting system [69]. 
5.2 Materials and Methods 
Materials 
Gelatin from porcine origin (type A), Tartrazine and trichlorofluoro-silane were purchased from 
Sigma. Poly (ethylene glycol) diacrylate with a molecular weight of 4000 kDa was purchased from 
Polysciences and Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) from TCI chemicals. 
Hanks Balanced Salt Solution and Phosphate Buffered Saline Solution were from Life technologies, 
and both complete Dubbelco’s cell culture medium and penicillin-streptomycin, together with 
Normocin were purchased from Gibco. Sylgard 184 elastomeric kit was purchased from Dow 
Corning and isopropanol from Panreac.  
SolusProto and ABS-like grey resins for both Solus and Phrozen 3D printers, respectively, were 
purchased from FEP shop.  
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5.2.1 Preparation of the hydrogel pre-polymer solution 
The prepolymer solution for the printing of hydrogels was prepared using the following reagents. 
First, gelatin methacryloyl was made by following the method described elsewhere [70], and mixed 
in the proper concentration with PEGDA, LAP and tartrazine. The mixture was dissolved in HBSS 
supplemented with 1% v/v of P/S at 65 ºC in stirring conditions. Once completely dissolved, it can 
be stored at 4ºC for later use or directly poured into the bioprinter cuvette to start the printing. In 
the case of embedding cells in the hydrogel, cells should be detached from the culture flask and 
resuspend in the proper concentration in the prepolymer solution just before being added to the 
cuvette for printing. All the system, including the bioink should be at 37ºC to guarantee high cell 
viability. 
5.2.2 Printing Methodology 
The printing process was carried out in a customized Solus 3D Printer. The works with a DLP 
projector reaching an XY resolution of 25 microns and a layer thickness down to 10 microns.  
First, the build platform was adapted to be able to place 13 mm diameter glass slides on it, as new 
supports for the prints. In the same way, the cuvette for the bioink (also referred to as vat) was 
redesigned to reduce the amount of solution required for printing (see Figure 5.5). In addition, a 
heater was coupled to the system to keep the bioink solution at 37ºC, avoiding bioink gelation and, 
at the same time reducing cell death. 
Before printing, the design to be printed has been created with CAD tools, specifically with FreeCAD 
and Autodesk Fusion 360. The designs were exported to *.stl format to be able to do the slicing of 
the design and print it layer by layer. In addition, printing parameters such as layer thickness and 
exposure time, among others, have also been adjusted to obtain the desired results. 
 
Figure 5.5. Modified Solus 3D printer used to perform the printings. 
5.2.3 Microfluidic platform 
The microfluidic platform is compromised of the microfluidic device and the casing (see Figure 
6.1). For the fabrication of the microfluidic device, PDMS was used. Briefly, PDMS prepolymer 
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solution was mixed in 10:1 (w/w) ratio with the cross-linking agent and poured into different sets of 
microstructured moulds (or masters) previously designed and 3D printed using a standard BSA-
like photocuring resin. Previously, the 3D-printed masters were treated with oxygen plasma for 15 
minutes and later with a vapor phase silane for 1 hour using. After a degassing step, the PDMS 
parts were cured at 85 ºC for 3 hours or 48 hours at room temperature to obtain the final elastomeric 
replicas. 
For the outer casing, a high-resolution LCD printer called Phrozen was used. With this printer, the 
different pieces compromising the outer casing of our microfluidic system were fabricated. After 
printing, they were cleaned with isopropanol and cured under UV for 2 minutes and let them rest 
for 60 minutes. 
5.2.4 Volumetric Swelling 
The water uptake capacity of the printed hydrogels was analysed both in static and dynamic 
conditions, by measuring their volumetric variations upon time, to optimize the shape and size of 
the hydrogels’ contour and their inner microstructures. 
Either Phosphate Buffered Saline Solution (PBSS) or DMEM cell medium were used. Immediately 
after printing, samples were rinsed in warmed PBS to remove unreacted polymer and placed at 
37ºC to reach the equilibrium swelling. Pictures from the top and lateral side of the gels were taken 
at different timepoints until reaching the equilibrium swelling, drying first the hydrogels with Kimwipe 
paper to avoid distortion. 
Four critical parameters were defined to determine the proper geometry of the intestinal crypts (see 
Figure 5.6), being parameter A the crypt depth, a the width of the crypts in the middle point, b the 
upper aperture of the crypts, and, c the distance between consecutive crypts. 
    
Figure 5.6. From left to right: Illustration of the relevant parameters used to quantify the size of the crypts and one example of the 
method. 
5.2.5 Gut-on-a-chip assembly 
The schematic of the assembly of the whole chip is depicted in Figure 5.7. Briefly, the first layer of 
PDMS was placed in the bottom part of the holder (step 1). In the same way, the 13 mm diameter 
glass coverslip with the previously printed hydrogel was then placed on top of the PDMS layer (step 
2). To guarantee the proper alignment of both parts, a circular allocation was included on the PDMS 
layer. With the alignment structures, the top layer of PDMS containing some of the microfluidic 
channels and the inlet and outlet cavities was placed upside down perfectly aligned with the ones 
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below (step 3). Finally, the cover was placed, on top fitted with some alignment structures and 
fastened with six screws to press against the PDMS ensuring proper contact all along the surface 
of the microfluidic chip (steps 4–5). The corresponding tubbing (step 6) and Leuer connectors were 
added together with a debubble allowing for the application of perfused flow avoiding undesired air 
bubbles. 
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6. DETAILED ENGINEERING. RESULTS AND DISCUSSION 
The results obtained have been organized in four stages that describe the progression of the 
microfluidic chip design and optimization: from the development of the casing and PDMS layers, to 
the characterization and selection of the bioink, to the optimization of the 3D structure of the 
hydrogels, to finally develop the chip assembly.  
6.1 Optimization of the structural part of the chip 
The gut-on-chip model has been done by integrating the hydrogel into a PDMS structure that will 
provide a casing for the hydrogel and contain the microfluidic channels of the chip together with the 
inlet and outlet. To provide structural integrity to the whole system, the PDMS is placed inside hard 
plastic pieces that will function as outer casing, fastening the whole system and ensuring that no 
leakages are present (see Figure 6.1). From the casing point of view, the main requirements were: 
a) to integrate the 3D bioprinted hydrogel containing embedded cells in a faster way once 
printed 
b) to be perfusable, so cell medium could flow for oxygen and nutrients exchange  
c) to be assembled and disassembled on demand in a simple and faster way  
d) to contain a transparent window to be able to inspect the inner of the channel using optical 
microscopy 
e) to be properly sterilized to be compatible with standard cells culture 
f) to be reusable 
It was considered that the best way to achieve the initial objectives was by creating two individual 
PDMS layers the printed hydrogel could fit in between, with space for the hydrogel and the 
corresponding microfluidics and an external structure that would allow the correct alignment of the 
PDMS layers and apply pressure on the PDMS layers to avoid leakage. Figure 6.1 shows the layers 
of the gut-on-chip from the structural point of view. 
 
Figure 6.1. Layers of the gut-on-chip for two-channel. 
ADRIÀ DÍAZ FERRERO 
Final degree project 
26 
 
6.1.1 External casing 
According to the initial objective, different 3D printed casings have been developed to meet the 
previous requirements. The casing is made up of two different pieces, the lower part (Figure 6.2 
left) that has an allocation where the PDMS pieces can be placed and some vertical motifs that will 
help on the correct alignment of the system. The upper part (Figure 6.2 right) will act as a lid, 
covering the PDMS and exerting pressure against them to avoid leakage. This is necessary since 
the two layers of PDMS do not contain any adhesive or surface activation. Initially, these two parts 
of the outer casing contained a rectangular central hole that acts as a transparent window for 
inspection (see Figure 6.2 right) 
Additionally, six through-holes were designed both in the cover and in the lower part to be able to 
place six screws. These screws are intended to seal and press the PDMS layers located at the 
bottom of the casing. 
       
Figure 6.2. Image of the two sections of the casing. From right to left: Bottom part and cover of the casing. 
After a first trial, results showed that the lid designed was not making the necessary pressure in 
the central region of the chip to avoid leakage between the two layers of PDMS. Two vertical motifs 
were added to the lid and bottom to exert more pressure in the hydrogel region (see Figure 6.3 
left). Then, the aperture left as the window was too big and some leakage appeared in this region. 
At that point, a third lid was designed to reduce the inspection area, covering more surface to make 
a better and more homogeneous pressure (see Figure 6.3 right). In this case, the transparent 
window cover both the inlet and outlet of the chip, the channel and the region above the hydrogel. 
 
Figure 6.3. From left to right: Illustration of the initial lid and the improvement made. 
Even the leakage was reduced in this third design, it was still present since the regions between 
the central window and the inlet and outlet cavities were not robust enough to ensure the desired 
pressure and bent upwards. The final design that was considered the best solution was the one in 
the figure below, in which the entire surface was covered except for the inlet and outlet openings 
and the area of the small central region where the hydrogel is placed (Figure 6.4). 
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Figure 6.4. Schematic and image of the final lid implemented on the gut-on-chip. 
In the same way, for the design of the two-channel lid, a design like the one in Figure 6.4 was 
made. The lid covered the entire surface except for the inlet and outlet openings and the central 
region. 
6.1.2 PDMS layers 
Polydimethylsiloxane (PDMS) is a polymer widely used for the fabrication and prototyping of 
microfluidic chips for its excellent properties. After the cross-linking process, PDMS becomes a 
hydrophobic and transparent material at optical frequencies, it is inexpensive, easy to cast, is 
considered biocompatible and has a low autofluorescence [71,72].  
PDMS is the key structure that will locate the hydrogel with the embedded cells and will create the 
microfluidic channel. As explained above (see Figure 6.1) the microfluidic chip is composed of two 
layers of PDMS. The bottom layer was designed with a cavity to allocate the circular glass coverslip 
in which the hydrogel is printed, avoiding any possible gap between the hydrogel and the channel 
that could alter the flow when introducing the fluid through the channel. Both the size and the 
thickness of this cavity were optimized considering the dimensions of the glass. The top layer 
presents the motive of the channel and the allocation for the hydrogel. 
All the PDMS layers present six orifices along the longitudinal sides (three on each side) and the 
allocation for the roundish cover glass in the centre (see Figure 6.5 and Figure 6.6). These holes 
are used as alignment marks, to perfectly fit the two layers of PDMS onto the external casing, 
avoiding mismatches. The designs of the casing and the PDMS were optimized to ensure that 
these orifices coincide with the casing axis (see the assembly layout in Figure 5.7).  
 
Figure 6.5. A) Image of one PDMS bottom layer. B) Illustration of the PDMS layer from a side view. 
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Figure 6.6. Image of one PDMS top layer. 
During the project, different types of photocurable resins were used to obtain the 3D moulds from 
which the PDMS layers were made. Initially, we used a BSA-like resin (ABS-like grey resin) 
sensitive to UV light, polymerized using a Phrozen Shuffle XL 3D printer, equipped with an array of 
405 nm wavelength LEDs (see left panel in Figure 6.7). This resin allows for the printing of moulds 
that can be heated up to 65ºC, so could be potentially used for the curing of PDMS at room 
temperature or in an oven less than 60ºC. However, it was found that the PDMS pieces obtained 
were irregular, a bit sticky and partially opaque (see middle panel in Figure 6.7). This was 
considered not suitable for our application since the PDMS had to be transparent. To solve this 
issue, the DLP-SLA Solus 3D printer was used, since its photosensitive resin (SolusProto) allows 
reaching temperatures up to 95ºC without deformation, resulting in PDMS replicas with high 
transparency (see right panel in Figure 6.7). 
 
Figure 6.7. Image of the different moulds used during the project. A) Mould made with the Phrozen printer. B) Replica obtained 
with the Phrozen moulds. C) Mould made with the Solus printer. 
During the project, two different microfluidic designs were studied and optimized. Initially, a single 
channel layout (Figure 6.8-A) which have one main channel with its corresponding inlet and outlet 
orifices, so that the hydrogel would only be in direct contact with the liquid from one side. This 
design also includes an extra channel on the opposite side of the cavity for the allocation of the 
hydrogel that would act as an outlet for the bubbles. On the other hand, a second layout with two 
channels was designed and fabricated (Figure 6.8-B), including a common inlet and outlet orifices. 
In this approach, the liquid will flow through both channels reaching the hydrogel from two sides, 
favouring its proper hydration and the nutrients exchange, especially when cells would be 
embedded in the gel. 
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Figure 6.8. Representation of the PDMS top and the mould used. A) Chip with one channel. B) Chip with two channels. 
When we have the layers of PDMS (Figure 6.8) we should make different holes to place the 
connections to the infusion pump and the waste. To do this, a 0.75 mm diameter medical punch 
was used. The syringes through which the cell medium was injected into the chip were placed in 
these inlets and outlets to facilitate circulation inside the chip. 
6.2 Bioink Selection 
The appropriate shape and distribution of the microstructures has been proved to be a key 
parameter for reaching proper cell arrangement and functioning, having a strong impact on the 
normal intestinal functions, drug absorption and mucus production, among others. [39] Thus, it is 
very important to include these topographic features in the in vitro models to better resemble the 
native tissue architecture. In this sense, the proper material selection will be of high importance to 
achieve this goal. As already reviewed in the introductory section, hydrogels are one of the most 
suitable candidates, since it allows a large variety of combinations and the possibility of tunning 
their composition on demand, to favour cells attachment and growth. Moreover, they can be 
microstructured using a large variety of techniques. In previous works, Vila et al. (2020) presented 
a hydrogel co-network based on GelMA and PEGDA polymers, and proved to have the required 
features to mimic the compartments of the intestinal mucosa, providing both structural support and 
cell-friendly motifs promoting cell adhesion and proliferation [3,73]. Inspired by their results, the 
composition of this GelMA-PEGDA blend was adapted for bioprinting, leading to a bioink 
photopolymerizable upon visible-light irradiation with precise control of x-y resolution. This was 
achieved by two different actions. First, lithium-phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) 
photoinitiator was added. This photoinitiator has a high-water solubility, and an absorption peak 
around 365 nm, which better matches the spectral range of our 3D bioprinter and the Vivitek 
projector [46]. Second, a photoabsorber was added to the hydrogel composition to control the light 
penetration into the highly transparent pre-polymer solution. In this case, Tartrazine, a synthetic 
lemon-yellow dye was chosen [49]. 
This new bioink allows for (i) a good microstructuring of the hydrogel and (ii) a homogeneous 
distribution of the cells once trapped within the printed gel.  
The concentrations of each of the elements in the pre-polymer solution should be previously studied 
taking into account cell viability, since the hydrogel will be the scaffold for future cells. Besides 
having the necessary properties for cells to live and grow on top and inside, the pre-polymer 
a b 
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solution should also be stable allowing the printing of complex 3D structures, such as crypts in the 
intestine, to mimic better the cellular microenvironment. Table 6.1 summarize the final 
concentrations of each of the bioink components, that were optimized based on previous studies 
performed in the laboratory. 
Table 6.1. Composition in percentage of the bioink used to develop the hydrogel. 
GelMA PEGDA LAP Tartrazine 
5 % 3 % 0.4 % 0.025 % 
6.3 Optimization of the channel design and the printing parameters 
As previously described, using the DLP-SLA 3D printing technique, objects are produced via layer-
by-layer illumination of the crosslinkable solution. The design of our gut-on-a-chip model was 
carried out considering only half of the section of the colon, including invaginations in the hydrogel 
mimicking the large intestinal crypts, leading to a luminal cavity comprised between the printed 
hydrogel and the PDMS boundaries (see schematics in Figure 6.9).  
 
Figure 6.9. Schematics of the gut-on-a-chip for the hydrogel including crypts and the channel comprised between the printed 
hydrogel and the PDMS boundaries. 
The fully optimized gut-on-chip model will comprise a central channel surrounded by 3D 
microstructured hydrogel at both sizes. However, the design was simplified for these initial stages, 
to focus our attention on optimizing the crypt-like feature sizes and the assembly of the hydrogel 
with the PDMS layers. 
6.3.1 Outer hydrogel dimensions  
The final size of the hydrogel has been optimized by performing various experiments. It is important 
to determine the magnitude of the swelling of our hydrogel due to the absorption of water, 
considering that PDMS is a stable material that cannot change its shape in case the hydrogel 
grows. It was also important to achieve almost identical dimensions to those of the designed cavity 
in the top PDMS layer to prevent the liquid from flowing through other places than the central 
channel. 
So, a first experiment was designed to study the volumetric swelling behaviour of the printed 
hydrogel to refine the outer dimensions. To do so, rectangular hydrogels with dimensions of 7 
millimetres long, 4 millimetres wide and a thickness of 700 microns were printed and kept in PBS 
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at 37ºC. Measurements of the hydrogels dimensions were performed at different time points to 
evaluate its change according to the process described above (see Section 5.2.4, methodology). 
Three replicates were evaluated. 
In this case, as the geometry of the prints was simple (just a rectangle) without any complex 
geometric features, the printing parameters were not as critical as in the case of the crypts 
optimization process. However, for later comparison when the crypts will be present, these 
parameters were kept constant, according to previous optimization studies carried out for other 
laboratory members. Thus, the printing parameters were set to 13 μm for the thickness of each 
printed layer, 15 seconds for the single layer exposure time for the first printed layers, and 5 
seconds for the rest of the layers. The bottom layers should be irradiated for a longer time to ensure 
a proper attachment of these layers to the glass. 
Changes in the dimensions of the hydrogels were measured immediately after printing (t=0) and 
after 15, 30, 60, 90, 120, 150 and 360 minutes. Figure 6.10 shows the results obtained (tables 
including all the measurements can be found as supplementary data in the Annexes section). 
 
Figure 6.10. Evolution of the three parameters studied in this experiment and the corresponding error for each measurement. A) 
Evolution of the thickness for the 3 samples, the x-axis corresponds to the time in minutes and the y-axis to the thickness in 
micrometres. B) Evolution of the width for the 3 samples, the x-axis corresponds to the time in minutes and the y-axis to the width 
in micrometres. C) Evolution of the length for the 3 samples, the x-axis corresponds to the time in minutes and the y-axis to the 
length in micrometres. D) Example of a rectangle hydrogel printed. 
Due to the hydrogel's own polymerization mechanisms, the initial dimensions of the X-Y prints are 
smaller (6.8 x 3.7 mm2, instead of 7 x 4 mm2) and the final dimensions obtained were 585.2 μm +/- 
6.9 μm in thickness, 3668.5 μm +/- 90.4 μm in width and 6811.7 μm +/- 114.9 μm in length, values 
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which represent 16.0%, -0.5% and 0.1% of variation, respectively. Greater growth in width and 
length was expected, more similar to that found in thickness.  
The most significant change occurs in the thickness of our hydrogel and the rest of the dimensions 
have not changed with respect to the initial measurements (t = 0). The estimation could be improved 
by carrying out more samples and for a longer time to confirm that in the final time the hydrogel 
does not grow any more. 
The dimensions of the cavity to house the hydrogel to the bottom layer of PDMS are kept at 7 x 4 
mm2, while the height is set at 600 μm, to guarantee an inner contact between the two layers of 
PDMS. These layers will restrict growth in Z and cause the hydrogel to grow in the XY plane, 
ensuring final contact between it and the PDMS walls. 
6.3.2 Crypts geometry 
Once determined the external dimensions of the hydrogel, we focused on the introduction of the 
crypts geometry on one of the long sides (7 mm) of the hydrogel (the one in contact with the luminal 
cavity), to replicate the structure and morphology of the large intestine [74,75] (see Figure 6.11). 
Taking into account the previous photopolymerization results using the hydrogel composition used 
in this work, we approach the crypts geometry in the CAD model as regular rectangular grooves all 
along one of the lateral sides of the hydrogel, keeping a thin layer of hydrogel underneath (Figure 
6.11 – A), covering the surface of the glass underneath. In this way, a “u-shaped” crypt section can 
be obtained after the chip assembly, when the top surface of the 3D printed hydrogel gets in contact 
with the second PDMS layer (see Figure 6.13 as an example). It is known that cells spread and 
grew better on top of hard substrates, so covering the bottom part of the crypts we will force them 
to colonize the hydrogel. Figure 6.11 shows the 3D CAD design of the hydrogel and the crypts 
used. As previously determined, the outer dimensions of the hydrogel were fixed as 7 x 4 mm2, 
with a thickness of 500 µm. The bottom layer mimicking the bottom part of the crypts was set to 
250 μm. The length, width and thickness of the hydrogel remained constant throughout the process. 
 
Figure 6.11. Different views of one of the 3D CAD designs used for printing the hydrogel with crypts: perspective (a), top view (b) 
and front view (c). 
To determine the dimensions of the crypts some optimization should be performed, varying mainly 
the following dimensions: the parameter A, which corresponds to the depth of the crypts and the 
parameters B and C, which correspond to the width of the crypts and the separation between 
them, respectively (see Figure 6.12). 
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Figure 6.12. Parameters A, B and C modified in the optimization process.  
As reviewed in the previous sections, the printing methodology is based on illuminating the bioink 
and the support, where the glass is placed, with enough light to allow the polymerization of the 
bioink. When working with such small sizes, it is possible that during the printing process, some 
undesired photopolymerization between the crypts may occur due to the intrinsic nature of the 
reaction-diffusion mediated photopolymerization [17] and the reduced distance between consecutive 
crypts. So different 3D CAD models were created to determine the most suitable values for A, B, 
and C parameters to obtain, after the integration of the hydrogel on the microfluidic chip, proper 
crypts definition. 
The range of values for the three crypt parameters, used for the optimization, are summarized in 
Table 6.2. Due to the resolution limit of our 3D bioprinter setup and the bioink used, crypts with 
smaller dimensions could not be obtained.  
Table 6.2. Tested ranges for the parameters A, B and C. 
Parameter A B C 
Tested Range (μm) 750 – 850 150 – 500 250 – 400 
In particular, two combinations of parameters were of great interest due to the results obtained, 
achieving a regular crypts distribution, and fixed as possible candidates for the final gut-on-chip 
design. The first one, with A = 850 μm, B = 150 μm and C = 400 μm (see Figure 6.13), gave rise to 
large aspect ratio crypts, deeper than wider, resembling more to what can be found in vivo. With 
the second combination, using A = 850 μm, B = 200 μm and C = 400 μm (see Figure 6.14), shorter 
but wider crypts were obtained, with a smooth variation of the curvature. The printing results were 
evaluated immediately after printing, after rinsing the hydrogel in warmed PBS to remove the 
unreacted polymer, and once constrained inside the chip. To better assess the final dimensions of 
the printed crypts, a 13 mm in diameter glass coverslip was place on top, mimicking the microfluidic 
chip assembly.  
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Figure 6.13. Printing results for crypts using B = 150 μm. A) Sketch of the 3D CAD model. The highlighted area corresponds to 
the regions shown in images B and C. B) Crypts immediately after printing with the crypts highlighted. C) Crypts after placing a 
glass coverslip on top, mimicking the chip assembly.  
 
Figure 6.14. Printing results for crypts using B = 200 μm. A) Sketch of the 3D CAD model. The highlighted area corresponds to 
the regions shown in images B and C. B) Crypts immediately after printing. C) Crypts after placing a glass coverslip on top, 
mimicking the chip assembly. 
In all cases, the printing parameters were kept constant, being the same ones as those used for 
the evaluation of the swelling effect in the hydrogel outer shape: 5 seconds for the layer exposure 
time, 15 seconds for the exposure time of the initial layers and a layer thickness of 13 μm.  
6.3.3 Hydrogel Characterization 
Similar to what we performed previously with the outer dimensions of the printed hydrogel; it is very 
important to evaluate the change in dimensions of the crypts and the hydrogel over time once 
integrated on the microfluidic chip and covered by cell culture media, due to the swelling 
phenomenon. Thus, the crypts’ dimensions could be adjusted. To determine the swelling in these 
conditions, hydrogels including both crypts’ designs were assembled on chip after printing (see 
Table 6.3). First, they were washed in warmed PBS and dried to avoid any residue during the 
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assembly. In this case, casings containing the two-channels design were used. To ensure the 
proper fitting of the hydrogel between the two PDMS layers and that the whole structure, including 
the outer casing, exerts the correct pressure to leak the channels and the hydrogel cavity, the 
thickness of the PDMS layers was adjusted. After the assembly, the entire chips were placed in the 
incubator at 37ºC and continuously perfused with cell culture medium for 96 hours, setting the flow 
to 2.5 µL/min. This flow rate was previously optimized for other purposes and is in agreement with 
what can be found in the literature for intestinal models. According to Bein et. al. 2018, the flow rate 
can mimic the dynamic ranges of fluid and associated shear stresses that are observed in the 
human intestine [2], so it is of great importance to include it in our model, to better replicate the in 
vivo conditions. This fluidic control allows to have a high spatio-temporal regulation on the delivery 
of nutrients and drug compounds among other factors, to the intestinal epithelium [2]. Figure 6.15 
shows, as example, an illustration of the two-channel design and the hydrogel sample 1 once 
assembled inside the microfluidic chip. The two-channel structure is visible and the hydrogel with 
the crypts can be clearly distinguished.  
Table 6.3 summarizes the crypt parameters and the other rectangular dimensions for both samples 
tested. As can be observed, the selected parameters for the crypts definition were larger than those 
previously optimized to be able to correctly examine the growth of the crypts, avoiding their collapse 
and clogging during the swelling process. 
Table 6.3. Size of the samples printed in the hydrogel characterization. 











Sample 1 850 300 400 7 4 
Sample 2 850 500 300 7 4 
 
Figure 6.15. Illustration of the two-channel chip design with the hydrogel after the assembly. 
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Graphs in Figure 6.16 show a comparison of the measured hydrogel dimensions for both sample 
types, just after the assembly (time = 0h) and after 96h. The final dimensions obtained were 7612.3 
μm +/- 6.6 μm in length and 4730.1 μm +/- 3.1 μm in width for sample 1 and 7691.0 μm +/- 26.8 μm 
in length and 4649.0 μm +/- 5.9 μm in width for sample 2. As observed, hydrogels contour grew 
significantly in both directions, resulting in an increase of 5.3% and 13.6% for sample 1, and 4.5% 
and 10.0% for sample 2, in length and width respectively. According to the results obtained, we 
have the biggest change in the width of the hydrogel since it grows through the channel. On the 
other hand, the length has varied less since it has PDMS walls which impede growth in that 
direction. Detailed values for the measurements can be found in the Annexes.  
 
Figure 6.16. Change in length and thickness after 96 hours of swelling. 
In the same way, the changes in the dimensions of the crypts for both samples were analyzed. 
Figure 6.18 shows the values obtained for the different parameters analyzed: A (which was 
previously defined in Section 5.2.4), a, b and c (see each parameter in Figure 6.17). These changes 
were more evident in sample 2, where crypts initially shorter than the ones in sample 1 get closed, 
reducing dramatically the depth of the evaginations (parameter A).  
 
Figure 6.17. Schematic of the relevant parameters used to quantify the size of the crypts. 
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Figure 6.18. Change in crypts size for the two samples. 
Most of the crypt parameters have been reduced due to swelling in both samples. Table 6.4 depicts 
the final dimensions and the corresponding error found in both samples for the four parameters 
specified in Figure 6.18. 
Table 6.4. Dimension changes and errors of each parameter of the crypts after 96 hours. 






 Final Dimensions (μm) 352.1 226.4 312.4 693.9 
Error (μm) ± 15.1 ± 4.8 ± 5.7 ± 15.3 






 Final Dimensions (μm) 434.0 419.1 550.6 825.1 
Error (μm) ± 21.2 ± 6.7 ± 10.6 ± 13.4 
Growth percentage - 38.7% - 10.1% 0.4% 0.8% 
The percentage of growth regarding the initial values at t = 0h, have a negative value since the 
swelling of the hydrogel has a positive sign and, therefore, the dimensions of the hydrogel are 
larger causing the dimension of the crypts to be smaller. 
Figure 6.19 shows pictures of both samples, sample 1 and sample 2, after 96h of swelling, once 
disassembled from the microfluidic chip. Here, the changes in dimensions are evident. As obtained 
from the measurements on-chip, crypts in sample 1 get closed and became shorter, being the 
parameter A the one that experienced the highest reduction. In sample 2 (Figure 6.19-B), however, 
crypts were more visible even the reduction since initially they were bigger. 
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Figure 6.19. Image of the hydrogel samples once removed from the microfluidic chip after 96 hours. A) Sample 1. B) Sample 2. 
Finally, we can conclude that the swelling of the hydrogel occurs more uniformly when it is inside 
the chip than when we perform the experiment outside the chip. Also, from the swelling-on-chip, 
we can deduce that, in percentage, the width of the hydrogel grows more than the length. This may 
happen because the width can grow more freely by having space with the channels while on both 
short sides, we have the PDMS walls which difficult the hydrogel to swell in those directions. For 
crypts, the most affected parameter is A, which is hugely reduced. This was expected since the 
reduction of parameters b and c, negatively affects this parameter. From Figure 6.19 it can be 
deduced that after the hydrogel swell, the geometry of the crypts become irregular and unequal in 
both samples. On one hand, the results obtained make us chose the sample 2 since it replicates 
better the intestinal crypts and keeps better the geometry of the crypts after swelling, although the 
parameters of the invaginations can be further optimized taking into account this data. On the other 
hand, sample 1 shows that the crypts have reduced their depth by 45%, which may indicate that 
these structures will not correctly replicate the shape and microstructure of the intestinal crypts. 
6.4 Gut-on-a-chip model 
Once all the components were optimized and integrated into the microfluidic system, there was 
only one step missing: include the cellular component to the model. Thus, a new set of hydrogels 
were printed including two of the most representative cell types of the intestine on them: CCD18-
Co, which are human colon myofibroblasts, and THP-1 monocytes, as representative cell line of 
the immune system. The aim of this experiment was to see if the cells embedded in the 3D printed 
hydrogel could survive once integrated inside the microfluidic chip. For this purpose, four different 
sets of chips were assembled, two of them with single-channel (see Figure 6.20–A) and two of 
them with the two-channels design (Figure 6.20–B). The inlet ports of the chip were connected to 
an infusion pump syringe that introduced complete cell culture medium at a constant flow rate. 
Between the pump and the inlet, we added a bubble trap, to avoid air bubbles circulating through 
the channels and get trapped inside the chip, altering the flow (see Figure 6.21).  
ADRIÀ DÍAZ FERRERO 




Figure 6.20. A) Illustration of PDMS for 1-Channel layout. B) Illustration of PDMS for 2-Channel layout. C) Side view of the chip in 
which we can see the channel formed between both PDMS layers and the hydrogel. 
 
Figure 6.21. A) Chip placed inside the incubator. B) Infusion pump outside the incubator to inject direct current flow. 
When the chips were assembled and before the application of the flow, some cell culture media 
was manually introduced by placing the tip of a needle at one side of the silicone rubber tube, which 
was directly connected to the bubble trap. The outlet of the bubble trap was directly connected to 
the inlet of the microfluidic chip. The culture media pumped out from the chip was evacuated from 
the system directly to a waste container (see Figure 6.21–A). Once the system was completely 
bled, the inlet of the bubble trap was connected to the infusion pump which started pumping media 
to the system. For this particular experiment, syringes with a volume of 15 mL were placed in each 
pump applying a flow rate of 2.5 μL/min.  
To increase the number of experimental replicates and see if the presence of cells could alter the 
swelling behaviour of the printed hydrogels, shape measurements were again performed to check 
the variations on dimensions of the crypts at different time points once assembled inside the 
microfluidic chip. Table 6.5 summarizes the initial dimensions of the chips and crypts used 
according to the previous A, a, b and c parameters described (see Figure 6.17). Figure 6.22 shows 
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the values of the four parameters measured for the crypts (A, a, b and c) just after the assembly 
(time = 0h).  
Table 6.5. Design Characteristics of microfluidic chips. 
Sample Number of Channels 
Crypts Parameters Outer Geometry 
A (μm) B (μm) C (μm) Length (mm) Width (mm) 
Sample 1 1 (Figure 6.20-A) 850 300 400 7 4 
Sample 2 1 (Figure 6.20-A) 850 500 300 7 4 
Sample 3 2 (Figure 6.20-B) 850 300 400 7 4 
Sample 4 2 (Figure 6.20-B) 850 500 300 7 4 
 
Figure 6.22. Dimensions of the four samples at initial time for the parameters A, a, b and c.  
The quantification of the parameters in Figure 6.22 was done with the hydrogel directly assembled 
on the chip. From these results, it is clear that the dimensions of the crypts at t = 0h differ with 
respect to the initial measurements made in previous experiments (see Figure 6.18). A possible 
explanation for this might be that the upper layer of PDMS does not come into contact with the 
hydrogel. This causes the crypts to not have the characteristic “U-shape” that we had in previous 
experiments where we made the measurements by placing a glass coverslip on top of the hydrogel. 
For this reason, the crypts parameters are slightly different compared with previous results. In 
addition, the variation in parameters A, a and b between samples 1 and 3 (which initially have the 
same crypts parameters) could be attributed to the absence of contact between the hydrogel and 
the PDMS which hindered the correct visualization of the crypt geometry. 
To monitor the cell activity inside the hydrogel-on-chip, pictures were taken at different timepoints. 
In particular, cells in Sample 2 were monitored 72 and 120 hours after bioprinting and chip 
assembly. Sample 1 was discarded due to assembly issues, that caused partial dehydration of the 
hydrogel. Figure 6.23 shows the evolution of the crypts of sample 2 in the three different timepoints. 
The points that can be seen in Figure 6.23, B and C correspond to the cells previously embedded 
in the hydrogel. 
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Figure 6.23. Design of one channel chip and the crypts at different timepoints (Sample 2). A) Crypts at the initial time, 0 hours 
after the bioprinting. B) Crypts after 72 hours at the incubator. Images taken with the microscopy; we can visualize embedded 
cells. C) Crypts after 120 hours at the incubator. Images taken with the microscopy; we can visualize embedded cells. 
For sample 2 most of the parameters have been reduced due to swelling. Table 6.6 depicts the 
dimensions at 72 hours and at 120 hours and the corresponding error for the four parameters. The 
percentage of growth has been calculated with the initial dimensions at t = 0h and the final 
dimensions (t = 120h). 
Table 6.6. Dimension changes and errors of each parameter of the crypts after 72 and 120 hours for the sample 2. 
  Parameter A Parameter a Parameter b Parameter c 
72 hours 
Dimensions (μm) 752.3 395.4 429.2 876.6 
Error (μm) 13.9 5.0 3.6 11.6 
120 hours 
Dimensions (μm) 693.4 375.6 433.4 874.4 
Error (μm) 10.6 9.8 6.2 5.7 
Growth percentage -10.7% -15.4% -10.5% 4.3% 
These values are not comparable to those reviwed in Table 6.4 because all measurements have 
been made on-chip, unlike the date in Table 6.4 where a glass coverslip was placed on top of the 
hydrogel. For this reason, the growth percentages differ between the two tables. It remains unclear 
if the presence of cells could alter the swelling behaviour of the printed hydrogels. 
Finally, several images of the chip were taken, specifically of sample 2 to verify that there was no 
leakage between the two layers of PDMS and that the hydrogel could be seen correctly from the 
central circular window (see Figure 6.24).  
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Figure 6.24. Microfluidic chip with a hydrogel after 120 hours. 
On the other hand, samples 3 and 4 were monitored only up to 2 hours after the bioprinting and 
assembly since they were used for performing cell viability analysis (data not included in this 
project). Figure 6.25 shows, respectively, examples from samples 3 and 4.  
 
Figure 6.25. Design of two-channel chip and the crypts at different timepoints for sample 3 (A and B) and sample 4 (C and D). A) 
Crypts at the initial time, 0 hours after the bioprinting (sample 3). B) Crypts after 2 hours at the incubator. Images taken with the 
microscopy; we can visualize embedded cells (sample 3). C) Crypts at the initial time, 0 hours after the bioprinting (sample 4). D) 
Crypts after 2 hours at the incubator. Images taken with the microscopy; we can visualize embedded cells (sample 4). 
To conclude, the results obtained in Figure 6.25 accords with our earlier observations in Figure 
6.24, which showed high viability rates of the cells. One interesting finding was that the crypts are 
still visible in the different samples after swelling (see Figure 6.24 and Figure 6.25). The images 
acquired from sample 2 were taken at a more advanced time, which provides us information 
regarding the geometry of the crypts after a swelling of 72 and 120 hours. On the other hand, for 
ADRIÀ DÍAZ FERRERO 
Final degree project 
43 
 
samples 3 and 4 the microstructure was more similar to the initial time as less time has passed. 
These results further support the idea that embedded cells tend to adapt their shape to the 
geometry of the crypts as time goes by (such as those cells in sample 2). This study has been 
unable to demonstrate differences regarding the swelling and cell viability between the two models 
designed (the one-channel and the two-channel chip). 
One concern about the findings of swelling on-chip was that the height of the hydrogel and the 
PDMS should guarantee a close contact between the two surfaces. Initially, we thought that growth 
in Z of the hydrogel would be enough to get that contact, however, more careful analysis and study 
of the swelling in the Z direction should be done. In addition, one limitation of these methods is that 
in some cases the close contact between both PDMS surfaces and the pressure exerted by the 
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7. IMPLEMENTATION SCHEDULE 
7.1 Work-breakdown Structure (WBS) 
In this section, we are going to review our Work-breakdown structure or WBS (Figure 7.1). It 
organizes the work into different manageable sections. In the Project Management Body of 
Knowledge, a set of standard terminologies for project management the WBS is defined as a 
"hierarchical decomposition of the total scope of work to be carried out by the project team to 
accomplish the project objectives and create the required deliverables" [76]. 
 
Figure 7.1. Work-breakdown structure of our project. 
7.1.1 WBS Dictionary 
Firstly, we are going to describe each of the activities created in the WBS (see Figure 7.1). In Table 
7.1 a brief description of the task that should be developed in each of the activities of the project is 
presented. In the first column, we can find the number associated with the WBS activity described 
in section 7.1 and the associated name. The last column corresponds to a concise description of 
each task. 
Table 7.1. Dictionaries to each of the activities created in the WBS. 
Nº NAME DESCRIPTION 
1 Casing Chip casing design and optimization 
2 PDMS 
Printing the moulds to create the PDMS layers. Familiarization with 
the creation of PDMS and optimization of the temperature and time 
that should be in the oven 
3 Bioprinting 
Adaptation of the Solus 3D printer to print hydrogels and bioink 
preparation besides performing the subtasks. The total duration of 
this task corresponds to the sum of the duration of the subtasks 
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Configuration of the different printing parameters, exposure times 




Optimization of the outer geometry of the hydrogel in order to 




Design and optimization of the geometry of the crypts. Definition of 
the parameters to be varied and the optimal range for each one. 





Experiment to see the evolution of the crypts and their swelling after 
a certain time. Familiarization with infusion pumps and the 
placement of inlets and outlets. 
5. Chip development 
Detection of failures or problems in the previous task and flow rate 
optimization. Measurement of all PDMS layers and printing of new 
casing with the right dimensions for the following tasks. 
5.1 One Channel Chip 
Assembly of two chips with a single channel with cells embedded in 
the hydrogel. 
5.2 Two Channel Chip 
Assembly of two chips with two channels with cells embedded in the 
hydrogel. 
7.2 Task Sequence Matrix 
First, we are going to determine the time associated with each activity (Table 7.2). The first column 
corresponds to the number of the activity associated with the WBS, the second column the activity 
sorted in alphabetical order and the next columns corresponds to: Pessimistic, Normal, Optimistic 
and Final time, respectively. Each row is associated with one activity, except tasks number 3 and 
5 since the times of these tasks are the sum of the subtasks. To determine the final time, we are 
going to use the next formula: 
𝑇𝑖𝑚𝑒𝑓𝑖𝑛𝑎𝑙 =
𝑇𝑜𝑝𝑡𝑖𝑚𝑖𝑠𝑡𝑖𝑐 + 𝑇𝑝𝑒𝑠𝑠𝑖𝑚𝑖𝑠𝑡𝑖𝑐 + 4 · 𝑇𝑛𝑜𝑟𝑚𝑎𝑙
6
 
Table 7.2. Data used to calculate the final time of each activity defined in the WBS. 
Nº ACT. PREVIOUS TIME NORMAL TIME OPTIMISTIC TIME FINAL TIME 
1 A 27 22 18 22 
2 B 21 19 18 19 
3 - 54 45 37 45 
3.1 C 6 3 2 3 
3.2 D 20 17 15 17 
3.3 E 28 25 20 25 
4 F 18 14 12 14 
5 - 28 22 18 22 
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5.1 G 12 9 7 9 
5.2 H 16 13 11 13 
The ordering of this matrix (Table 7.3) has been done according to the activities in alphabetical 
order. Each activity has its corresponding numbering, according to the EDT dictionaries, its 
preceding and consequent activities, and the duration, in days. In addition, the initial and the final 
dates are also represented in days. Using this matrix, we will obtain the PERT and GANTT 
diagrams.  
Table 7.3. Task Sequence Matrix, in the first column the number associated with the EDT, in the second column the letter associated 
with each activity, followed by the preceding, consequent activities and the duration. The last two correspond to the start and end 
date. 
Nº NAME ACT. PREVIOUS CONSEQUENT DURATION INITIAL FINAL 
1 Casing A ... B 22 0 22 
2 PDMS B A F 19 22 41 
3 Bioprinting - - - 45 0 45 
3.1 Setting printing Parameters C … D 3 0 3 
3.2 Rectangle Optimization D C E 17 3 20 
3.3 Crypts Optimization E D G 25 20 45 
4 Hydrogel Characterization F B G 14 41 55 
5 Chip Development - - - 22 55 77 
5.1 One Channel G E,F H 9 55 64 
5.2 Two Channel H G … 13 64 77 
7.2.1 PERT Diagram 
In this section, the Program (or project) Evaluation and Review Technique (PERT) is presented 
(Figure 7.2). The PERT helps us to estimate and judge how well it is going by calculating the length 
of time needed for each of the events involved in the project. Each node has an associated number 
and the Early and Last time. The lines in red represent the critical path which means that if this path 
is delayed the whole project will be delayed. 
 
Figure 7.2. PERT diagram associated with the sequence matrix, with the “Early” and “Last" times indicated in each node and the 
critical path marked in red. 
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7.2.2 GANTT Diagram 
The GANTT chart (Figure 7.3) shows the start and finish dates of the tasks and it will help us to 
monitor specific tasks. This diagram has been made considering the PERT diagram and the task 
sequence matrix. A total time of 77 working days has been obtained to perform the different tasks 
of the project. Figure 7.3 shows that Bioprinting has a duration equal to the sum of subtasks 3.1, 
3.2 and 3.3, in the same way as the task of Chip Development with the subtasks 5.1 and 5.2. 
 
Figure 7.3. GANTT diagram of our project. 
Considering that the calculated times (third column of Table 7.4) correspond to working days, we 
have calculated each activity’s start and end date. In these calculations, it has been considered 
that the project will be carried out on working days and weekends are excluded. Table 7.4 shows 
the start and end date, and the total days that we will spend on each activity. The experimental part 
of the project will end on May 19, 2021. 
Table 7.4. Table considering the working days. 
Nº ACT. WORKING DAYS TOTAL DAYS START DATE END DATE 
1 A 22 30 01/02/2021 03/03/2021 
2 B 19 27 03/03/2021 30/03/2021 
3 - 45 63 01/02/2021 05/04/2021 
3.1 C 3 3 01/02/2021 04/02/2021 
3.2 D 17 25 04/02/2021 01/03/2021 
3.3 E 25 35 01/03/2021 05/04/2021 
4 F 14 20 30/03/2021 19/04/2021 
5 - 22 30 19/04/2021 19/05/2021 
5.1 G 9 11 19/04/2021 30/04/2021 
5.2 H 13 19 30/04/2021 19/05/2021 
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8. TECHNICAL PREVIABILITY 
The project has been developed at IBEC and therefore all the equipment and facilities have been 
obtained from there. 
8.1 Technical Challenges 
8.1.1 Bioprinting 
The development of bioprinting is an emerging technology with many advantages but, also has 
many technical challenges that need to be overcome soon. On one hand, the correct selection of 
the bioink is essential. An ideal bioink should possess proper mechanical, chemical and biological 
characteristics. Nowadays, some biomaterials used such as collagen or fibrin gel are not developed 
for bioprinting which makes it a bioink with low physical and biological conditions. One alternative 
to avoid these limitations is the creation of hydrogel-based bioink, which has numerous advantages 
such as cell attachment, spreading, growth and differentiation [49]. 
IBEC developed a new hydrogel-based bioink before explained which provides the required 
features for cells to attach and grow, improving the biological and physical conditions of the current 
standard in vitro models for the small intestinal mucosa [3]. In particular, the designed hydrogel 
allows mimicking both the epithelial and the stromal compartments, providing a cell 
microenvironment that favours interactions between both cellular compartments [3]. To create this 
hydrogel, the synthesis and characterization of GelMA is needed. Then a photo-polymerization 
reaction using an ultraviolet (UV) of 365 nm of wavelength and co-networks should be performed 
between the GelMA and the PEGDA (Figure 8.1) [3]. 
 
Figure 8.1. Schematic adapted from Vila et. al. 2020, of the GelMA and GelMA-PEGDA photo-polymerization reaction and co-
networks formed. [3] 
Even though the bioprinting technology presents a unique opportunity to produce biomimetic 
cellular structures the current capacity to produce 3D structures using multiple types of cells, 
biomaterials, and biomolecules is limited [77]. The lack of the capability to produce structures that 
completely mimic the tissue structure might cause that the phenotypes and responses of the human 
intestine do not reproduce as accurately. The incorporation of limited components and limited type 
of cells of the intestinal compartments, and their associated features, might play a significant role 
in some disorders [2]. If these technical challenges are overcome, bioprinting will likely be a way to 
produce OoC systems in the near future, helping to develop better disease models and achieve 
personalized medicine. 
8.1.2 PDMS 
The chosen material to create the microfluidic channel and which will contain the hydrogel had to 
be (i) transparent, to enable the continuous monitoring and analysis of the hydrogel, (ii) 
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biocompatible and (iii) should be fabricated with a simple method but allowing a high resolution to 
replicate small structures. PDMS provides a few advantageous features for our microfluidic chip in 
front of other materials such as glass. As we have reviewed in previous sections, PDMS can be 
easily fabricated through a moulding process, is a transparent, soft and a flexible material and is 
commonly used due to its low cost. A technical challenge that we have found during the chip 
development are the leaks. The system developed is based on two layers of PDMS without any 
treatment or adhesive. The system has a casing that is responsible for exerting pressure at the two 
layers to prevent leakage. This is done to be able to disassemble the chip and get back the printed 
hydrogel in addition to being able to reuse the PDMS. This could be complicated in case of 
treatment on its surface or using adhesives.  
The main problem of not performing any process is that the layers of PDMS may have leakage that 
may depend on many factors, including if the pieces are clean, the speed at which the liquid is 
introduced in the chip, if both surfaces are completely flat or the pressure exerted to join both layers 
during assembly, among others.  
8.2 SWOT Analysis 
The SWOT analysis is a strategic planning technique that helps to identify the strengths, 
weaknesses, opportunities, and threats of a project. In this case, the SWOT Analysis is done in 
Table 8.1. 
Table 8.1. SWOT Analysis of the 3D bioprinting technique developed in this project. 
Strengths Weakness 
- 3D bioprinting of microstructures 
- High resolution 
- Could replace animal experiments 
- Wide range of bioprinters and methods 
of bioprinting 
- Biocompatible Bioink 
- Chip easy to assemble and 
disassemble 
- Quality of the printed gut  
- Low maturity of the bioprinting 
technique  
- Slow maturation of the field 
- The bioprinting process is still long 
and slow 
- Difficult to completely replicate the 
desired structures 
- Leakage between the layers of 
PDMS 
Opportunities Threats 
- Huge market potential 
- Search for alternatives to animal 
experiments 
- Starting to become more affordable 
- Increasing demand 
- Early-stage technology 
- Validation systems are crucial to its 
adoption to a regulatory process 
- High initial cost 
8.2.1 Internal Analysis 
Some of the strengths of the project are the ability to print microstructures with 3D technology with 
a high resolution, with a solution (bioink) that is biocompatible for cells and with a printing method 
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that allows you to print the cells embedded in the hydrogel and print a specific design. In addition, 
the hydrogel is set on a device which is easy to assemble and disassemble and the introduction of 
fluid is simple through syringes. Finally, the method of manufacturing the chips is cheap and simple, 
using 3D printers to perform the casing and moulds and PDMS for the microfluidic channel. 
On the other hand, there are also some weaknesses that should be overcome. Firstly, the printing 
process is still long and slow and some parameters such as humidity or temperature need to be 
studied to determine if they can affect the printing process and thus, its reproducibility. In addition, 
leaks are a weakness that should be solved to have a functional chip and that allows to study the 
evolution of the hydrogel and the embedded cells.  
8.2.2 External Analysis 
Some of the opportunities of the project are the demand from pharmaceutical industries and 
regulatory companies to adapt the OoC technology in drug development, safety screening and 
disease modelling [54], which is clearly increasing. According to the results obtained from the 
ORCHID program [54,61], the OoC's represent the fast-growing multidisciplinary field in the last 
decades in lab-on-chip, stem cell, microfluidics and biosensors development technology. Moreover, 
the efforts already obtained in standardization can lay the foundation for the standardization and 
qualification of OoC systems [54]. 
On the other hand, the OoC presents some threats such as, the systems are complex multi-
parametric implementations that try to answer the complex networked responses of the biological 
tissue. Also, not in all the OoC technology or process are currently efforts to standardize [54]. Finally, 
the comparison of the data obtained with OoC with the current animal models might interrupt the 
fast adaptation of OoC's by stakeholders, and thus slow down standardization [54,57]. 
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9. Economic Previability 
In this section, the total economic costs of the project are reviewed. Since it is a previous project, 
the costs have been approximated using the information proportioned by IBEC. The total cost of 
the project includes the cost of developing a gut-on-a-chip, and also the salary of the workers. In 
Table 9.1 is reviewed the material and the workers needed to develop the whole project. To develop 
it we need people formed in distinct areas such as: biomedical or industrial engineering, biology 
and chemistry. To compound this cost estimation, it has been considered the length of the project 
(commented in Section 7) and the number of hours that would work each employee, since no all 
would take part in the same developmental stages of the project, and some would work jointly. 
The necessary workers to develop the project are: two Biomedical Engineers one focused on the 
cellular part and the other focused on the bioprinting process. Also, a Chemist to develop the 
GelMA-PEDGA and a Biologist specialized in cell culture are needed. Since the duration of the 
creation of the hydrogel and the cell culture required are different, each specialist's time will be 
different. In addition, an industrial engineer is required to optimize all 3D printing processes, he 
would be in charge of the control and maintenance of the printers and give support in these aspects. 
The equipment and software needed to develop the project is the Solus 3D printer, reviewed in 
previous Sections, the software of the company and the Phrozen Shuffle XL 3D printer. In addition, 
a computer to connect the printers and download the software is needed. The light source used to 
solidify the liquid polymer layer by layer in the Solus printer will be a Vivitek 1080P DLP Projector. 
Furthermore, other material costs for the chip development, the creation of the PDMS and the 
hydrogel will be required. Additionally, for the development of the project, various consumables 
have been used, which have been given a generic price. 
Finally, two types of cells will be used, mouse embryonic fibroblasts and human leukemic 
monocytes. To obtain a monolayer of epithelial cells to recreate the Colorectal adenocarcinoma 
disease. In this case, the selected cell lines are frozen and have a Level 1 of biosafety [78]. 
Table 9.1. Approximation of the total cost of the project. 
CONCEPT UNITS UNIT PRICE TOTAL 
WORKERS    
BIOMEDICAL ENGINEER 2 14 €/h (500h) 14000 € 
BIOLOGIST 1 14 €/h (400h) 5600 € 
CHEMIST 1 14 €/h (250h) 3500 € 
INDUSTRIAL ENGINEER 1 14 €/h (400h) 5600 € 
EQUIPMENT    
SOLUS 3D PRINTING EQUIPMENT 1 3173 € 3173 € 
PHROZEN SHUFFLE XL 3D 1 1300 € 1300 € 
COMPUTER 1 500 € 500 € 
DLP PROJECTOR 1 1000 € 1000 € 
ADRIÀ DÍAZ FERRERO 
Final degree project 
52 
 
MATERIALS    
PDMS ELASTOMERIC KIT 1 313 € 313 € 
PEGDA 1 165 € 165 € 
LAP 1 125 € 125 € 
TARTRAZINE 1 35 € 35 € 
TRICHLOROFLUORO-SILANE 1 92 € 92 € 
OTHER REAGENTS 1 150 € 150 € 
PHROZEN RESIN 2 80 € 160 € 
SOLUS RESIN 2 200 € 400 € 
SCREWS AND TOOLS 1 200 € 200€ 
CONSUMABLES    
SYRINGES 
1 350 € 350 €  





SOFTWARE    
SOLUS SOFTWARE 1 91 € 91 € 
PHROZEN SOFTWARE 1 - - 
IMAGE J 1 - - 
FREECAD 1 - - 
AUTODESK FUSION 360 2 - (*) - (*) 
CELLS    
NIH-3T3 MOUSE EMBRYONIC 
FIBROBLASTS (CELL LINE) 
1 451 € 451 € 
THP-1 HUMAN LEUKEMIC 
MONOCYTES (CELL LINE) 
1 595 € 595 € 
TOTAL   37800 € 
Note: (*) Student Licence.    
According to the GANTT and PERT Diagram, the chemist will be doing the first task, creating the 
GelMA-PEGDA, this task can be supported by one of the biomedical engineers. The second part, 
the cell culture of both populations will be done by the Biologist, also supported by one of the 
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engineers. During the process of cell culture, the design of the 3D structure, the optimization of the 
printer parameters and the design of the casing should be done by one of the biomedical engineers 
together with the industrial engineer. On the other hand, one of the biomedical engineers should 
optimize the process of creation of PDMS and the chip. Finally, the process of bioprinting, 
optimization and microfluidics should be done by both biomedical engineers. 
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In this project, we reviewed the recently developed microfluidic gut-on-chip model and described 
the advantages that the proposed model offers with respect to commonly used 2D in vitro culture 
systems, including its ability to emulate more closely the 3D microstructure and function of the living 
human intestine. In addition, we have reviewed and compared various bioprinting techniques to 
polymerize and obtain this characteristic 3D microstructure of the intestine using photo-
crosslinkable materials such as hydrogels. 
The purpose of this research was to determine the feasibility of a microfluidic chip to mimic the 
intestinal mucosa. The study carried out has been able to confirm that the printing method selected 
to perform the project, based on stereolithography combined with digital light projector (SLA-DLP) 
3D printing, together with a proper bioink selection, are suitable to create 3D microstructures on 
hydrogels, resembling the human large intestinal crypts. Furthermore, it has been observed high 
compatibility of hydrogels and of the printing method, allowing for the printing of hydrogel-based 
structures with embedded cells, that can grow and populate the hydrogel keeping high viability 
rates (>90%). 
Firstly, for the development of the microfluidic chip, the design and optimization of the casing was 
carried out. The casing has been designed to store the two PDMS layers which in turn contains the 
hydrogel. The analysis of the outer part leads to the following conclusions: (i) the optimized casing 
exerts pressure on the PDMS layers, (ii) for some chips, the pressure exerted by the casing has 
been adequate to avoid leakage. Considering this, the initial objectives regarding the outer part of 
the chip have been met, but there are remaining issues subject to leakage that should be overcome. 
Next, the PDMS layers moulds containing the hydrogel and form the microfluidic channels were 
designed. The main conclusions that can be drawn are that an accurate temperature and time to 
solidify the PDMS were found and that the layers were capable of housing the hydrogel inside. The 
major limitation of the study was the appearance of leakage between both PDMS layers, this can 
have various origins and causes the chip to become non-viable. As we have argued elsewhere, 
the correct placement of the glass coverslip with the printed hydrogel in the bottom layer of PDMS 
can be a key aspect, as well as the dimensions of the gap where the glass is placed. On the other 
hand, the hydrogel had to be printed centred on the coverslip glass to match the motifs on the 
PDMS layer. Otherwise, it was possible for the PDMS to get on top of the hydrogel. The results of 
this research support the idea that it is necessary to use adhesives or activate the PDMS surfaces 
to be able to completely avoid leakage.   
One of the more significant findings to emerge from this project are the printing parameters 
optimized to achieve proper 3D microfeatures and the outer hydrogel dimensions. The findings of 
this study suggest that both aspects are optimum. The research has also shown that the optimized 
crypts geometry resembles what can be found in vivo. Despite having optimized this geometry, the 
growth of the hydrogel was studied with larger geometry to correctly examine the growth of the 
crypts and avoid their collapse. The evidence from the swelling data suggests that the crypts 
geometry must be optimized considering the size changes that occur in the hydrogel due to the 
swelling. Considerably more work will need to be done to determine the optimal crypt geometry. 
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Recent research on our microfluidic chip has provided a more complete understanding of the gut-
on-a-chip technology. Notwithstanding the limitations, the results indicate that the embedded cells 
can survive inside the chip for more than 120 hours and are able to adapt to the 3D microstructure 
of the hydrogel. The findings of this research provide insights on the fluidic conditions which 
guaranteed adequate micro-environmental conditions within the chip, allowing the exchange of 
cellular media. Consequently, the results of this project support the idea that there are no significant 
differences between the design formed by one channel and the design composed by two channels. 
More studies must be carried out for a longer time and increasing the sample size to be able to 
determine if there is a real difference between both designs and the cells are in better conditions 
in one of the two. 
10.1 Future work 
In future works, it should be considered that for this project only one side of the channel was 
studied. The formation of the channel was achieved by having the hydrogel on one side and the 
PDMS wall on the other side. In future research, it could be considered that the hydrogel constitutes 
both sides of the channel. By having hydrogel on both sides and a central channel, the printing 
parameters must be adjusted very well to keep the cavity of the channel and the crypts open and 
with certain dimensions. In addition, the optimization process must consider the dimensions just 
after the printing and when the hydrogel has swollen. Lastly, a greater focus on the dimensions of 
the channel size could produce interesting findings. Besides, further work is needed to fully 
understand their implication in our model. 
With the aim of completely mimicking the 3D structure of the crypts, a further approximation can be 
made. The next step would be to close the crypts both above and below, to generate cavities within 
the hydrogel, surrounded by material all around as found in tissue in vivo. 
One of the biggest challenges of the project was to ensure the sealing of the system while designing 
a device that could be easily assembled and disassembled and to recover the hydrogel without 
damage it to perform further studies, such as immunostaining of specific markers. In this way, 
PDMS layers surrounding the hydrogel could not be activated by plasma to enhance the bonding 
neither adhesive layers could be used, leading to some leakage between both layers. Further 
research should be carried out to establish the best methodology to prevent leakage which could 
include, a) the activation of both PDMS surfaces, b) use of adhesives to complete seal both layers, 
c) changing the microfluidic chip material to meet the new requirements. 
Further research might explore including representative cells of the intestinal epithelium that grow 
on top of the hydrogel and cover it, colonizing the crypts, in this way the model could be completed, 
at the cellular level. Based on this, there are many studies that can be performed, such as the effect 
of different flow rates on cell growth, which could facilitate the optimization of the dimensions of the 
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Following, complementary information of the project is presented. 
11.1 Optimization of the Rectangle 
These are the data obtained in the experiment to optimize the size of our hydrogel (Section 6.3.1). 
Each table corresponds to the three printed samples and we have the time at which the 
measurement was made, the thickness, width and length and the error associated with each 
measurement. 
















0 522.00 5.77 3442.86 51.64 6716.00 35.34 
16 552.86 4.19 3848.14 24.92 6784.14 103.21 
30 568.71 15.07 3672.57 46.16 6951.29 40.14 
65 522.43 4.54 3691.57 66.57 7302.71 23.44 
93 585.14 4.75 3502.00 34.31 7273.29 56.95 
124 611.86 7.62 3713.71 57.24 6919.00 26.07 
150 570.14 9.26 3853.86 60.90 6890.71 22.14 
378 596.43 3.00 3774.71 38.55 6934.00 27.64 
















0 508.14 3.20 3689.57 42.56 6794.29 30.57 
16 536.57 6.50 3667.29 50.81 6760.71 25.69 
30 610.86 5.89 3612.43 45.12 6786.00 27.54 
45 567.86 5.23 3676.57 38.53 6643.00 26.89 
58 557.71 12.80 3721.71 51.47 6877.86 33.35 
94 634.86 12.31 3521.71 46.86 6883.71 19.70 
119 674.29 13.77 3608.86 54.14 6685.43 60.33 
150 637.14 7.30 3578.14 55.82 6582.71 65.02 
377 586.57 9.16 3742.14 37.63 6919.00 22.80 
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0 474.86 5.53 3925.86 50.31 6902.57 38.14 
16 597.14 9.37 3634.00 34.72 6755.86 19.83 
32 601.57 3.72 3685.00 22.84 7022.29 34.86 
58 598.29 3.01 3535.57 27.25 6761.57 47.69 
88 618.00 3.08 3545.43 17.54 6647.00 31.86 
116 562.00 8.24 3898.86 23.96 6999.57 36.75 
379 572.57 11.49 3488.57 40.16 6582.00 45.13 
11.2 Hydrogel Characterization 
Data obtained in the experiment to perform the Hydrogel Characterization (Section 6.3.3). We can 
find the length and width of the hydrogel and the parameters A, a, b and c, before and after the 
swelling and the associated error. The first table corresponds to the Sample 1 and the second to 
the Sample 2. 
Table 11.4. Data of the hydrogel characterization for the sample 1. 
 Time 0 (0 hours) Time 1 (96 hours) 
Parameter Measurement (μm) Error Measurement (μm) Error 
Length 7230.04 7.22 7612.29 6.60 
Width 4163.74 10.46 4730.14 3.12 
A 637.72 6.56 352.14 15.06 
a 284.76 7.52 226.43 4.78 
b 383.02 8.72 312.43 5.71 
c 698.13 3.71 693.86 15.31 
Table 11.5. Data of the hydrogel characterization for the sample 2. 
 Time 0 (0 hours) Time 1 (96 hours) 
Parameter Measurement (μm) Error Measurement (μm) Error 
Length 7357.39 8.42 7691.00 26.76 
Width 4225.30 6.98 4649.00 5.89 
A 708.46 15.56 434.00 21.22 
a 466.07 6.77 419.14 6.72 
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b 548.17 18.85 550.57 10.62 
c 818.77 11.78 825.14 13.38 
11.3 Assembly of the microfluidic chip 
Data obtained in the experiment to perform the assembly of the microfluidic chip (Section 6.4). We 
can find the parameters A, a, b and c, at the initial time for four samples and the associated error 
for each measurement. There are two types of chips of one and two channels. 
Table 11.6. Data of the microfluidic chip assembly for all the samples at initial time (0 hours). 










Sample 1 600.28 36.68 238.64 3.74 269.34 4.08 740.03 10.08 











Sample 3 790.96 6.58 290.88 8.94 331.17 5.29 742.72 9.27 
Sample 4 814 6.57 456.46 12.92 519.80 12.35 849.95 7.23 
 
